



# Host succinate inhibits influenza virus infection through succinylation and nuclear retention of the viral nucleoprotein

Antoine Guillon, Deborah Bréa-Diakite, Adeline Cezard, Alan Wacquiez, Thomas Baranek, Jérôme Bourgeais, Frédéric Picou, Virginie Vasseur, Léa Meyer, Christophe Chevalier, et al.

## ► To cite this version:

Antoine Guillon, Deborah Bréa-Diakite, Adeline Cezard, Alan Wacquiez, Thomas Baranek, et al.. Host succinate inhibits influenza virus infection through succinylation and nuclear retention of the viral nucleoprotein. 2022. hal-03687124v1

**HAL Id: hal-03687124**

**<https://univ-tours.hal.science/hal-03687124v1>**

Preprint submitted on 3 Jun 2022 (v1), last revised 24 Nov 2022 (v2)

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

**Host succinate inhibits influenza virus infection through succinylation and nuclear retention of the viral nucleoprotein**

Running Title: *Anti-influenza activity of succinate*

Total characters count (including spaces): 96470

Antoine Guillon<sup>1,2,3\*</sup>, Deborah Bréa-Diakite<sup>1,2\*</sup>, Adeline Cezard<sup>1,2\*</sup>, Alan Wacquiez<sup>1,2</sup>, Thomas Baranek<sup>1,2</sup>, Jérôme Bourgeais<sup>2,4,5</sup>, Frédéric Picou<sup>2,4,5</sup>, Virginie Vasseur<sup>1,2</sup>, Léa Meyer<sup>6</sup>, Christophe Chevalier<sup>6</sup>, Adrien Auvet<sup>1,2,3</sup>, José M. Carballido<sup>7</sup>, Lydie Nadal Desbarats<sup>8</sup>, Florent Dingli<sup>9</sup>, Andrei Turtoi<sup>10,11,12</sup>, Audrey Le Gouellec<sup>13</sup>, Florence Fauvelle<sup>14,15</sup>, Amélie Donchet<sup>16</sup>, Thibaut Crépin<sup>16</sup>, Pieter S. Hiemstra<sup>17</sup>, Christophe Paget<sup>1,2</sup>, Damarys Loew<sup>9</sup>, Olivier Herault<sup>2,4,5§</sup>, Nadia Naffakh<sup>18§</sup>, Ronan Le Goffic<sup>6§</sup> and Mustapha Si-Tahar<sup>1,2\*</sup>

<sup>1</sup>INSERM, Centre d'Etude des Pathologies Respiratoires (CEPR), UMR 1100, Tours, France

<sup>2</sup>Université de Tours, Tours, France

<sup>3</sup>CHRU de Tours, Service de Médecine Intensive Réanimation, Tours, France

<sup>4</sup> CNRS ERL 7001 LNOx “ Leukemic niche and redox metabolism ”, Tours, France

<sup>5</sup>CHRU de Tours, Service d'Hématologie Biologique, Tours, France

<sup>6</sup>Virologie et Immunologie Moléculaires, INRAe, Université Paris-Saclay, Jouy-en-Josas, France

<sup>7</sup>Novartis Institutes for BioMedical Research, Basel, Switzerland

<sup>8</sup>UMR 1253, iBrain, Université de Tours, Inserm, Tours, France.

<sup>9</sup>Institut Curie, PSL Research University, Centre de Recherche, Laboratoire de Spectrométrie de Masse Protéomique, Paris, France

<sup>10</sup>Tumor Microenvironment Laboratory, Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, Montpellier, France

<sup>11</sup>Institut du Cancer de Montpellier, Montpellier, France

<sup>12</sup>Université de Montpellier, 34000 Montpellier, France

28 <sup>13</sup>University Grenoble Alpes, CNRS, CHU Grenoble Alpes, Grenoble INP, TIMC-IMAG, 38000  
29 Grenoble, France

30 <sup>14</sup>UGA/INSERM U1216, Grenoble Institute of Neurosciences, Grenoble, France.

31 <sup>15</sup>UGA/INSERM US17, Grenoble MRI Facility IRMaGe, Grenoble, France.

32 <sup>16</sup>Institut de Biologie Structurale (IBS), University Grenoble Alpes, CEA, CNRS, 38044, Grenoble,  
33 France.

34 <sup>17</sup>Department of Pulmonology, Leiden University Medical Center, Leiden, Netherlands.

35 <sup>18</sup> Institut Pasteur, Unité Biologie des ARN et Virus Influenza, CNRS UMR3569, Paris, France

36 \*: contributed equally to this work

37 §: contributed equally to this work

38

39

40 **\*Correspondence:**

41 Mustapha Si-Tahar, Centre d'Etude des Pathologies Respiratoires, INSERM U1100, Faculté de  
42 Médecine - 10, boulevard Tonnellé, 37032 Tours cedex

43 Phone: (00 33 2)47 36 60 45; Fax: (00 33 2)47 36 60 49; si-tahar@univ-tours.fr

## ABSTRACT

Influenza causes considerable morbidity and mortality, but current therapies have limited efficacy. We hypothesized that investigating the metabolic signaling during influenza may help to design innovative antiviral approaches. Using bronchoalveolar lavages of infected mice, we demonstrated that influenza virus induces a major reprogramming of lung metabolism. We focused on mitochondria-derived succinate that we found to accumulate both in the respiratory fluids of virus-challenged mice and of patients with influenza pneumonia. We found that succinate displays a potent antiviral activity *in vitro* as it inhibits the multiplication of influenza A/H1N1 and A/H3N2 strains and strongly decreases virus-triggered metabolic perturbations and inflammatory responses. Moreover, mice receiving succinate intranasally showed reduced viral loads in lungs and had increased survival compared to control animals. The antiviral mechanism involves a succinate-dependent post-translational modification, *i.e.* succinylation, of the viral nucleoprotein (NP) at the highly conserved K87 residue. Succinylation of NP could alter its electrostatic interactions with viral RNA and could further impair the formation and trafficking of viral ribonucleoprotein complexes. Hence, succinate efficiently disrupts the influenza replication cycle; this opens up new avenues for improved treatment of influenza pneumonia.

**Keywords:** antiviral / influenza / metabokine / signaling / virus

## INTRODUCTION

In 1918, more than 50 million people died from severe influenza viral pneumonia. One century later, and despite considerable progress in medicine, annual epidemics are still estimated to result in 3 to 5 million cases of severe illness worldwide and up to 650,000 deaths (Taubenberger *et al*, 2019, Lampejo, 2020). Influenza viruses are the etiological agents and are classified into four types (A, B, C and D) of which influenza A virus (IAV) is clinically the most significant.

Vaccination against influenza constitutes the most effective preventive strategy. However, the short duration of vaccine-induced immunity coupled with the intrinsic antigenic drift of IAV negatively affect vaccine efficiency (Jang and Seong, 2019). Besides, drugs targeting IAV neuraminidase (NA) are currently recommended by the WHO but their efficacy is largely disputed (Jefferson *et al*, 2014 ; Duwe, 2017). Hence, the development of innovative antiviral drugs is required to better treat IAV pneumonia (Pizzorno *et al*, 2019). To this end, we need a better understanding of the mechanisms of IAV-host cell interactions that may lead to IAV-triggered lung hyper-inflammation. Indeed, several studies suggest that such an excessive and deleterious inflammatory response is responsible for the life-threatening “flu” syndrome (Le Goffic *et al*, 2006 ; Taubenberger *et al*, 2019).

Interestingly, accumulating data support the view that metabolic pathways may promote or inhibit immune and inflammatory responses (Infantino *et al*, 2019; Rambold & Pearce, 2018; Williams & O’Neill, 2018), in addition to their role in energy production and macromolecular biosynthesis. Succinate is of special interest in this context. It is an intermediate of the tricarboxylic acid (TCA) cycle in mitochondria. Succinate is mainly produced from succinyl coenzyme A by succinyl coenzyme A synthetase (Grimolizzi & Arranz, 2018). It can also connect intracellular metabolic status and intercellular communication, as it can be released into the extracellular space through plasma membrane transporters of the SLC13 family (Grimolizzi & Arranz, 2018; Murphy & O’Neill, 2018). As a result, succinate can accumulate extracellularly in certain pathophysiological situations such as chronic inflammatory diseases (Ryan *et al*, 2019). Thus, the relationship between succinate and inflammatory signaling in leukocytes is increasingly studied (Tannahill *et al*, 2013; Mills *et al*, 2016; Littlewood-

Evans *et al*, 2016; Zasłona & O'Neill, 2020; Rubic *et al*, 2008; Jha *et al*, 2015). In contrast, such effects of succinate on non-immune cells such as the epithelial cells that line the airway mucosa have not been explored to a similar extent. This is important since airway epithelial cells are the main site of infection for respiratory pathogens such as IAV, and their role in controlling immune and inflammatory responses is pivotal. Furthermore, we and others have previously demonstrated that these cells are the source of major inflammatory mediators contributing to IAV-related lung injury (Gregory & Kobzik, 2015; Si-Tahar *et al*, 2009; Simmons & Farrar, 2008; Denney & Ho, 2018).

In view of the pro-inflammatory properties of succinate (Tannahill *et al*, 2013; Mills *et al*, 2016; Littlewood-Evans *et al*, 2016; Zasłona & O'Neill, 2020; Rubic *et al*, 2008; Jha *et al*, 2015), we initially speculated that succinate could contribute to the deleterious immunopathological response associated with severe IAV pneumonia. Strikingly, the opposite situation was observed. Using *in vitro* and *in vivo* approaches, we reveal that succinate restricts IAV replication and downstream inflammatory signaling. The underlying mechanism involves a specific post-translational modification and nuclear retention of the IAV nucleoprotein (NP). Hence, we demonstrate that succinate is a key player in the antiviral defense of the lung mucosa.

## RESULTS

### Influenza infection increases succinate levels in airways

Despite the growing interest in immunometabolism (Pearce & Pearce, 2018), little is known about metabolic reprogramming upon IAV infection (Wendt *et al*, 2021; Keshavarz *et al*, 2020; Smallwood *et al*, 2017; Bahadoran *et al*, 2020; Tian *et al*, 2019). Here, we conducted an unbiased quantification of the lung metabolome of mice four days after the infection by a sub-lethal dose of IAV (A/Scotland/20/74 (H3N2)). From the nuclear magnetic resonance (NMR) spectra of the bronchoalveolar lavage (BAL) fluids, we focused on succinate for two main reasons: (i) it was among the top ten most altered metabolites in the BAL fluids of IAV-infected mice, compared to control animals (fold change = 2.2, FDR-adjusted p-value =  $8 \cdot 10^{-7}$ , Figure 1a) and (ii) succinate is increasingly recognized as a potent immunoregulatory mediator (Tannahill *et al*, 2013; Mills *et al*, 2016; Littlewood-Evans *et al*, 2016; Zasłona & O'Neill, 2020; Rubic *et al*, 2008; Jha *et al*, 2015).

In agreement with the data from the mouse experiments (Figure 1a), succinate level in respiratory fluids (*i.e.* tracheal aspirates) was significantly higher in critically ill patients with influenza infection than in patients not infected by IAV but with similar severity and lung inflammation (Figure 1b). This second group of patients included critically ill individuals ventilated for coma (cardiac arrest, stroke or drug overdose) with similar comorbidities and severity score, as assessed by IL-6 and IL-8/CXCL8 measurements in the respiratory fluids (Figure 1c), the leucocyte count in respiratory fluids and the regular presence of positive bacterial culture (Figure 1d). The heterogeneity of succinate levels in the fluids of IAV-infected patients can partly be ascribed to the variability at the time of hospital admission and the subsequent symptoms-to-sampling time (median [IQR] = 9 [7; 18] days). Overall, we demonstrated that IAV infection was associated with high levels of succinate in lungs of mice and humans.

### Succinate limits the secretion of inflammatory mediators and restores metabolic dysregulation in IAV-infected lung epithelial cells

To decipher the potential role of succinate in IAV-infected lungs, we first compared at 20 h post-infection (pi) the gene expression profiles of IAV-infected human bronchial epithelial cells, exposed or not to succinate. The volcano plot in Figure 2a (*left panel*) shows that IAV infection increased the expression of multiple gene pathways, including canonical immune and inflammatory pathways. The volcano plot in the *right panel* indicates that succinate treatment of IAV-infected cells results in a drastic downregulation of those pathways. As illustrated in Figure 2a and in [Appendix](#) figure S1, those altered pathways included, but were not limited, to “inflammasome signaling”, “TREM1 signaling”, “acute phase response signaling”, “role of PRR in recognition of bacteria and viruses”, “iNOS signaling”,...). Of note is that succinate does not induce any cell cytotoxicity at the doses we used ([Appendix](#) Figure S2a-b).

We considered that the decrease of inflammatory pathways mediated by succinate in the context of IAV infection was an important observation for two reasons: first, because inflammation is a key promoter of IAV pneumonia and lung function impairment (Gregory & Kobzik, 2015; Si-Tahar *et al*, 2009; Simmons & Farrar, 2008; Denney & Ho, 2018); second, because so far succinate was mostly considered to be pro-inflammatory (Tannahill *et al*, 2013; Mills *et al*, 2016; Littlewood-Evans *et al*, 2016; Zasłona & O’Neill, 2020; Rubic *et al*, 2008; Jha *et al*, 2015). Using a semi-quantitative approach (*i.e.* protein-array blots), we confirmed that succinate limits the secretion of various inflammatory mediators (Figure 2b). Then, we quantified the diminution of critical inflammatory cytokines by succinate and found that this metabolite decreases down to 75% IAV-mediated secretion of IL-6, IL-8, IP-10/CXCL10 and RANTES/CCL5 (Figure 2c). Consistently, malonate (*i.e.* a selective inhibitor of succinate dehydrogenase (SDH) which favors endogenous succinate accumulation (Mills *et al*, 2016; Potter & Dubois, 1943)) also inhibited IAV-induced inflammatory response (as assessed by IL-6 quantification (not illustrated)).

Because viruses are known to take control of the host metabolism to replicate more efficiently (Keshavarz *et al*, 2020), we also wanted to examine whether succinate could prevent IAV-induced metabolic reprogramming. We first measured the IAV-induced changes in glycolysis and mitochondrial oxidative phosphorylation using a Seahorse™ analyser. We observed that IAV significantly impaired the oxygen consumption rate (OCR) (*i.e.* a key metric of mitochondrial



oxidative phosphorylation) and the extracellular acidification rate (ECAR) (*i.e.* an index of the glycolytic activity) (Figure 2d-e, pink dots). After succinate treatment, IAV-induced metabolic dysregulation tended to be corrected, with a trend towards the normalization of both glycolysis and mitochondrial oxidative phosphorylation (Figure 2d-e, green dots). Together, these results showed that succinate inhibited both the inflammatory and metabolic perturbations secondary to IAV infection.

### **Succinate blocks the multiplication of IAV in lung epithelial cells**

Next, we wondered whether the effects of succinate in IAV-infected cells were due to its immunomodulatory rather than its anti-infective properties. To answer this question, we challenged lung epithelial cells with synthetic double-stranded RNA poly(I:C) (PIC), which is a potent agonist of TLR3 signaling that mimics IAV-triggered immune responses (Guillot *et al*, 2005). Poly(I:C) induced IL-6 and IL-8 secretion at a similar or even higher level than IAV does. However, succinate did not inhibit poly(I:C)-induced secretion of these cytokines and chemokines (Figure 3a). We further compared the production of viral particles in the supernatants of IAV-infected epithelial cells exposed or not to succinate, in terms of viral neuraminidase (NA) enzymatic activity or viral titers. We observed a marked reduction of IAV load upon succinate treatment in distinct human airway epithelial cells (such as BEAS-2B (Figure 3b-c), 16HBE14o- and A549 cells (Appendix S4)). These results were further confirmed by a decrease of neo-virion budding and release, as assessed by electronic microscopy (Figure 3d and Appendix Figure S3). Interestingly, the treatment of IAV-infected lung epithelial cells with succinate or malonate resulted in a similar reduction of NA activity (Figure 3e). We confirmed and extended these findings by showing that succinate impairs IAV multiplication even more strongly in multicycle replication condition (using a MOI=10<sup>-3</sup>; ~5-fold decrease) than in single cycle replication condition (using a MOI=1; ~2-fold decrease; Figure EV1a-b). Overall, we demonstrated that succinate inhibits IAV multiplication.

### **Succinate protects mice from IAV pneumonia**

We further explored whether we could confirm *in vivo* the anti-influenza effect of succinate that we revealed *in vitro*. Mice were infected intranasally with a LD50 of A/Scotland/20/74 (H3N2) IAV and received or not succinate (4 mg/animal). Figure 4a-c shows that viral load and viral protein expression in lung tissues were lower in succinate-treated mice at 4 days pi. To assess concomitantly the possible modulation of the immune/inflammatory response by succinate, we first evaluated the relative expression of 111 mediators in the BAL compartment (Figure 4d and Appendix Figure S5). Eighty-four of these mediators were increased upon IAV infection, and almost all, including chemokines, cytokines and metalloproteases, were markedly reduced in succinate-treated animals (Figure 4d). A more accurate quantification of IL-6 and KC by ELISA confirmed the semi-quantitative protein-array findings (Figure 4e). Consistently, the amount of inflammatory cells such as neutrophils and myeloperoxidase (a protein primarily released by neutrophils) were significantly reduced in succinate-treated animals (Figure 4f-g; see also Appendix Figure S6 for the leukocyte gating strategy)).

IAV-mediated damage of the lung mucosa results from a combination of intrinsic viral pathogenicity and an inappropriate regulation of host immune mediators (Le Goffic *et al*, 2006; Simmons & Farrar, 2008; Blanc *et al*, 2016). Therefore, by histopathological scoring, we explored the effect of succinate on lung tissue aspect. We observed a significant decrease of IAV-induced alveolar wall thickening, and hyaline membrane and epithelial necrosis in mice that received succinate compared to control, infected animals (Figure 4h). Finally, mice infected by a LD50 of IAV started to lose weight at 5 days pi (Figure 4i) and ultimately 40 % succumbed (Figure 4j). Mice that received succinate did not lose weight and all survived.

### **The anti-IAV effect of succinate involves a retention of the NP protein in the nuclear compartment**

To better understand how succinate inhibits the production of viral particles, we studied its impact on the different stages of the replication cycle of IAV by first using experimental conditions yielding a single round of IAV infection (MOI=1). After entry, the virus cycle starts by the transcription of viral mRNAs (Figure 5a). These viral mRNA serve as a template for the translation of viral proteins. We observed a comparable amount of viral M1 mRNAs in non-treated and succinate-treated cells, as assessed by RT-qPCR (Figure 5b). By contrast, when lung epithelial cells were infected under

experimental conditions that support multicycle IAV replication ( $\text{MOI}=10^{-3}$ ), succinate induces less viral M1 transcripts due to a lower number of re-infecting virus particles (Figure EV1, panel c). The effect of succinate on the subsequent stages of the viral cycle was examined using single replication conditions. A similar viral protein expression pattern was found in non-treated and succinate-treated cells, as assessed by western-blot analysis of the viral NP, NS1, PB2, PA, M1 and M2 proteins; (Figure 5c). The lack of a succinate effect on IAV mRNA and protein expression led us to analyze the impact of such metabolite on viral proteins trafficking. We especially examined the effect of succinate on (i) the nuclear import (or nucleo-cytoplasmic shuttling) of newly synthesized viral proteins and (ii) the nuclear export of newly assembled viral ribonucleoproteins (vRNPs) complexes (Figure 5a). We performed real-time imaging using an NS1-GFP-tagged recombinant IAV (A/WSN/33 (H1N1)), which shows similar replication and virulence properties to its wild-type counterpart (not illustrated). In the absence of succinate treatment, we typically observed a fluorescent signal in the cytosol of IAV-infected lung epithelial cells at ~6 h pi. This was followed by progressive nuclear accumulation of the signal (at ~10 h pi). Ultimately, we observed a diffuse fluorescence signal, as well as vacuolization accompanying cell death at >22 h pi (Figure 5d-e; see also [Movie EV1](#) for visualization of the complete process). In contrast, in succinate-treated cells, the fluorescent signal seemed to be more restricted to the nuclear compartment and cytoplasmic vacuolization accompanying cell death was reduced (Figure 5d-e and [Movie EV2](#)). Thorough quantification carried out on 60 cells confirmed that the nuclear/cytoplasmic fluorescence ratio was significantly higher in succinate-treated cells than in control cells (Figure 5f).

We next studied whether the nuclear retention of NS1 by succinate could be extended to other viral proteins. Using confocal microscopy, we monitored at 20h pi the intracellular localization of NS1 as well as of PA, PB2, M2, M1 and NP proteins in lung epithelial cells infected by IAV (A/Scotland/20/74 (H3N2)) and exposed or not to succinate. We first confirmed that NS1 shows a selective nuclear accumulation in succinate-treated cells. Remarkably, we extended this observation to NP by confocal microscopy (Figure 6a) [as well as by flow cytometry \(Figure EV2\)](#). Those findings were further supported by the accurate quantification of NS1 as well as of NP relative nuclear

intensities (Figure 6b). In contrast, PB2, PA, M2, M1 proteins were essentially localized in the cytosolic compartment in both control- and succinate-treated lung epithelial cells (Figure 6c). Interestingly, when lung epithelial cells were infected by a distinct IAV strain, *i.e.* A/PR/8/34 (H1N1), succinate caused nuclear retention only of NP and not of NS1 (Figure 7a) while it did inhibit viral multiplication, as assessed by the measurement of NA activity ( $p < 0.05$ ; Figure 7b). Succinate also caused nuclear retention of NP in cells infected with an NS1-deficient PR8 strain of virus (*i.e.* “PR8  $\Delta$ NS1”) (Figure 7c). Taken together, these data suggested that NP retention, and not NS1, is key in the anti IAV-effect of succinate.

### **Succinate reduces the assembly of vRNPs but does not alter the CRM1-dependent transport pathway**

Since NP has been shown to interact with the CRM1-mediated nuclear export pathway (Elton *et al*, 2001), we examined whether succinate could affect CRM1 protein expression or function. As shown in **Figure EV3a**, CRM1 levels in IAV-infected cells remained the same, whether these cells were exposed or not to succinate. Next, we compared the effect of succinate and leptomycin B (LMB), a specific CRM1 inhibitor, on the trafficking of the viral NEP/NS2 protein. This last protein is known to be translocated into the cytosol in a CRM1-dependent manner (Kudo *et al*, 1999, 1998). As expected, nuclear export of NEP/NS2 was inhibited by LMB. In contrast, succinate did not alter NEP/NS2 localization, indicating that succinate does not mimic the CRM1-dependent effects of LMB (**Figure EV3b**). Hence, these data suggest that succinate causes nuclear retention of NP, in a CRM1-independent way.

NP is a major structural component of vRNPs. Viral (v)RNAs are encapsidated by NP with approximately 12 nucleotides *per* NP molecule (Dou *et al*, 2018). NP oligomerization is likely to be involved in the higher order structure of vRNPs (Elton *et al*, 1999). We used a non-denaturing western-blotting approach to test whether succinate could alter NP oligomerization. **Figure EV3c** clearly shows that this is not the case.

## **Succinate induces succinylation of NP at K87, a highly conserved amino acid involved in vRNA binding**

Next, we evaluated the impact of succinate on the interaction of NP with the vRNA. To this end, we used confocal microscopy and a monoclonal antibody that specifically recognizes the “NP-vRNA” complexes, but not unbound NP (Eisfeld *et al*, 2011), as illustrated in Figure 8a (*upper right panel*). Remarkably, succinate clearly reduced the fluorescence signal that marks NP-vRNA complexes but not the fluorescence signal associated to the total form of NP (Figures 8a (*lower panels*) and 8b). These results suggested that succinate reduces the assembly of vRNPs. We further questioned what could be the underlying molecular mechanism.

As a precursor of succinyl-coenzyme A, succinate can promote protein post-translational modification (PTM) *via* succinylation on lysine residues (Park *et al*, 2013; Xie *et al*, 2012; Yang & Gibson, 2019). Lysine succinylation can cause a mass change (~100 Da) and converts a positively charged side chain into a negatively charged one, potentially causing changes in protein structure and function. Therefore, we used liquid chromatography coupled to untargeted tandem mass spectrometry (LC-MS/MS) to examine whether succinate induced the succinylation of IAV proteins, especially NP. Notably, of all IAV proteins, only NP showed lysine succinylation in cells treated with succinate. Moreover, NP succinylation occurred at a unique residue, *i.e.* K87 (Figure 8c and Appendix Figure S7).

In regard to these latter data as well as those highlighting the impact of succinate on vRNPs assembly (Figure 8a), it is of interest to point out that K87 residue is located in the RNA-binding groove of NP (Ye *et al*, 2006). Hence, two types of experiments were further performed to assess the functional impact of succinate-induced NP succinylation on (i) the formation of NP-vRNA complexes and (ii) the intracellular trafficking of NP.

In line with lysine succinylation of K87, fluorescence anisotropy analysis showed that a recombinant K87E mutant NP (which bears a negative charge similar to a succinyl residue) interacts less with 6-mer and 12-mer polyUC RNA strands than wild-type NP does (Figure 8d). Moreover, reverse genetic experiments showed that an IAV mutant strain bearing a K87E NP is not replicative (not illustrated), suggesting that the positively charged K87 is critical in IAV life cycle.

Conversely, we used reverse genetics and confocal microscopy to monitor the localization of NP protein in lung epithelial cells infected either by a wild-type IAV strain (coined “NP K87”) or an IAV mutant (coined “NP K87R”; *i.e.* a virus which can normally replicate as assessed by PFU assay and qPCR (Appendix Figure S8) but carries an NP that cannot be succinylated at the aminoacid position 87, due to the lysine-to-arginine substitution (Park *et al*, 2013; Xie *et al*, 2012; Yang & Gibson, 2019)). Cells were exposed or not to succinate. We first confirmed that succinate induces a significant nuclear retention of NP in cells infected with the “NP K87” IAV strain (Figure 8e, *upper panels*). By contrast, succinate could not impair the intracellular trafficking of NP in cells infected by the mutant “NP K87R” IAV strain (Figure 8e, *lower panels*). Those findings were supported by an accurate quantification of NP relative nuclear intensities (Figure 8f). Besides, viral titer measurements in epithelial cells infected by “NP K87R” strain indicated that this mutant virus is significantly more resistant to succinate treatment than wild-type K87 IAV ( $p < 0.01$ ; Figure 8g). Altogether, our results suggest that succinate-induced alterations of IAV life cycle involves a succinylation of NP at the lysine residue 87.

## DISCUSSION

In the present study, we highlight the interplay between immunometabolism and antiviral immunity. Using a combination of *in vitro* and *in vivo* approaches, (i) we demonstrated that succinate accumulates in the airways of IAV-infected mice as well as in patients with influenza illness; (ii) we found that this metabolite displays a potent and specific antiviral effect; (iii) we revealed that succinate induces a unique succinylation of the viral NP residue K87, which probably impairs vRNPs assembly and accounts for the observed retention of NP in the cell nucleus and disruption of the viral replication cycle; (iv) we showed that instillation of succinate in the airways protects hosts from IAV-triggered acute pneumonia. Hence, we have confirmed and extended previous studies that revealed profound metabolic changes in lung fluids of patients (Cui *et al*, 2016b) as well as in mice (Cui *et al*, 2016a; Smallwood *et al*, 2017; Chandler *et al*, 2016) infected by IAV. Our findings are consistent with studies suggesting that viruses can reprogram host cell metabolic pathways (Eisenreich *et al*, 2019). Remarkably, our PCA and multivariate statistics showed that succinate is one of the predominant metabolites that accumulates in the lungs of IAV-infected hosts. Also, we established that succinate accumulation was restricted to the lung airspaces as succinate levels were not increased in the lung parenchyma compartment (not illustrated). This latter finding suggests that succinate modulates influenza pathogenesis by acting on cells of the top layer of the lung mucosa. However, further studies are needed to clarify which cell(s) is/are the major source of succinate accumulation in the airways and whether this is a repercussion of a dysregulated TCA catabolism and/or a higher extracellular transport of succinate.

Of note is that extracellular succinate increases in several pathological contexts with local tissue levels reaching up to 20 mM (Littlewood-Evans *et al*, 2016; Graham *et al*, 2013). This concentration is consistent with the non-cytotoxic and active amount of succinate that demonstrates an antiviral effect in our study.

TCA cycle-derived metabolites are not mere intermediates for ATP synthesis but have recently been demonstrated to play a critical immunomodulatory role (Zasłona & O'Neill, 2020). In particular, succinate has been identified as a crucial pro-inflammatory signal that regulates the transcription factor HIF-1 $\alpha$  in several leukocyte subtypes (Tannahill *et al*, 2013; Mills *et al*, 2016; Littlewood-Evans *et al*,

2016; Zasłona & O'Neill, 2020; Rubic *et al*, 2008; Jha *et al*, 2015). Regarding non-leukocyte compartments, succinate is considered an ulcerative, pro-inflammatory molecule in intestinal mucosa (Connors *et al*, 2018). In contrast, extracellular succinate might also mediate anti-inflammatory responses in neural stem cells as well as in adipose tissue resident macrophages (Keiran *et al*, 2019). Now, we extend these findings by revealing a downregulatory effect of succinate in IAV-triggered inflammation in lung epithelium.

IAV is known to replicate within the nucleus of lung epithelial cells (Dou *et al*, 2018). To this end, the viral proteins need to fold correctly, oligomerize and/or associate with each other. The neo-synthesized vRNPs have to be properly transported across the nuclear membrane and through the cytoplasm and be packaged into new virions (Dou *et al*, 2018). Here, we have clearly shown that succinate induces a nuclear retention of NP, a major component of vRNPs.

NP is a highly basic protein whose surface displays many positively charged amino acids such as lysines, which bind the negatively charged vRNAs. Therefore, NP is the main structural component of the vRNPs. X-ray crystallographic analysis of NP structure has previously characterized an “intrinsically disordered region (IDR)-2” (72-DERRNKYLEEHPSAGKDPKKT-92), located in an RNA-binding groove that exhibits the highest conservation ratio among human, swine, and avian IAVs (Kakisaka *et al*, 2016). In that regard, K87 is extremely conserved (>99.9%) among 2400 (H5N1), 23400 (H3N2) and 18800 (H1N1) IAV strains (source: Influenza research database; <https://www.fludb.org>; selection criteria: (i) complete coding region sequences; (ii) no geographical or temporal restrictions; (iii) no host discrimination (iv) no elimination of duplicates; not illustrated).

IAV is known to interact with the host cellular machinery, including the post-translational modifications (PTMs) components. The most common PTMs include phosphorylation, ubiquitination, SUMOylation, acetylation, methylation, NEDDylation, and glycosylation. Many PTMs foster influenza virus infection, whereas others can contribute to antiviral defense (Hu *et al*. 2020).

Remarkably, succinate triggers a unique succinylation modification of K87 in NP, whereas none of the other ten major IAV proteins were found to be succinylated. Our findings further support the hypothesis that K87 is a critical amino acid in the “IDR-2” of NP, in agreement with previous data showing that a K87A change in NP results in a decreased binding affinity for RNA (Kakisaka *et al*, 2016; Tang *et al*,



2021). Moreover, we found that (i) a NP with a K87E mutation (which bears a negative charge, mimicking a succinyl residue) interacts less efficiently than the wild-type NP with a synthetic RNA and (ii) succinate treatment results in a lower RNA-NP assembly. All these data are schematized in Appendix Figure S9. This is in line with the fact that IAV life cycle is not impaired by succinate-induced lysine succinylation in epithelial cells infected by a virus strain bearing an NP K87R substitution. Taken together, these data strongly point to the fact that succinylation of the NP-K87 could alter the electrostatic environment of the vRNA interaction site and could further impact the formation of vRNPs particles.

Concomitantly, we found that succinate treatment does not modify the accumulation of viral mRNAs or viral proteins, indicating that transcription and replication of the viral genome by the viral polymerase in the nucleus of infected cells is essentially unaffected, despite the altered NP-RNA interaction. In the presence of succinate, the CRM1-dependent nuclear export machinery is not inhibited either. However, NP appears to be retained in the nucleus, the levels of vRNP-associated NP in cytoplasm are decreased, and budding of viral particles and the production of infectious virions are strongly impaired. In view of these data, we propose a hypothetical model (Figure 9) in which succinylation of NP at the highly conserved K87 residue promotes a charge shift in the RNA-binding groove. This alters the encapsidation of vRNAs with NP in a way that preserves transcription/replication of the viral genome and the nuclear export of a vRNPs moiety (as suggested by the cytoplasmic staining of NEP/NS2 and the polymerase subunits at late time-points of the infection). It remains to be determined whether NP succinylation affects the packaging of the viral genome into viral particles. However, this proposal is consistent with the evidence that packaging of the segmented viral genome is governed not only by a complex network of RNA-RNA interactions but also by specific RNA-NP interactions (Bolte *et al*, 2019; Moreira *et al*, 2016).

Regarding a limitation of our study, we have to mention a similar survival of mice infected by wild-type IAV or by the mutant K87R IAV. This suggests that *in vivo*, the antiviral effect of succinate is likely the result of not only the impairment of IAV trafficking in lung epithelial cells but also the induction of additional protective signals in lung cell subsets, such as resident and/or infiltrated leukocytes.

395 Determination of the underlying signaling mechanisms and the cells involved in the global antiviral  
396 effect of succinate will therefore require further exploration.

397 In conclusion, our study demonstrates that IAV infection increases succinate levels in the airways and  
398 that this metabolite reduces IAV production through mechanisms that involves a specific post-  
399 translational modification. This further contributes to an inhibition of viral multiplication as well as  
400 viral-induced inflammatory response. More importantly, IAV-infected mice treated intranasally with  
401 succinate show increased resistance to the development of acute pneumonia. Hence, our study paves the  
402 way for the development of safe and promising succinate-based treatment of IAV infection.

## METHODS

**Viruses.** Mouse adapted-influenza A/Scotland/20/74 (H3N2) was generously given by Pr. Sylvie van der Werf's team (Pasteur Institute, Paris, France). The influenza A/PR/8/34 (H1N1) wild-type and  $\Delta$ NS1 strains were kindly provided by Dr. Georg Kochs (Freiburg University, Germany). Influenza A/WSN/33 (H1N1) wild-type and NS1 flag-tagged viruses were produced in Dr. Bernard Delmas' team (INRAe, Jouy-en-Josas, France).

**Animal infection and fluid collection.** C57Bl/6 female mice were purchased from the Centre d'Elevage R. Janvier (Le Genest Saint-Isle, France) and were used at about 8 weeks of age. Mice were treated in accordance with the European animal welfare regulation. Mice were bred in an animal facility in pathogen-free conditions. Mice were fed normal mouse chow and water *ad libitum* and were reared and housed under standard conditions with air filtration. When needed, C57Bl/6 mice were challenged intranasally with 150 pfu of A/Scotland/20/74 (H3N2) IAV. At 4 days post-infection, airways were washed four times with 0.5 ml of PBS for BAL collection. After centrifugation, BAL fluids were stored at -80°C for subsequent measurement of inflammatory mediators and pellets were recovered in PBS 2% FBS. Erythrocytes were discarded using a red blood cell lysis buffer and leukocytes were counted and analyzed by flow cytometry. Lungs were crushed with 2 mL of PBS using Gentle MACS™ M tube and the Gentle MACS™ Octo Dissociator (Miltenyi Biotech). Lungs extracts were centrifugated 5 min at 500 g to collect supernatants which were further stored at -80°C for subsequent Western-blotting.

**Metabolomic analysis of respiratory fluids using <sup>1</sup>H-nuclear magnetic resonance.** Freeze-dried BAL samples were mixed with 210 µl of 0.2 M potassium phosphate buffer in deuterium oxide (D<sub>2</sub>O) 99%, pH=7.4. Samples were spiked with 8 µL of 3-trimethylsilylpropionic acid (0.05 % wt in D<sub>2</sub>O) as an internal reference, and then samples were transferred to conventional 3 mm NMR tubes. <sup>1</sup>H-NMR spectra were obtained with an AVANCE III HD 600 Bruker spectrometer equipped with a TCI cryoprobe (Bruker). Standard water suppressed <sup>1</sup>H-NMR spectra were acquired at 298K using a “noesypr1d” pulse sequence with a relaxation delay of 20 s and 256 scans. Spectra were processed using Topspin software (Bruker). <sup>1</sup>H-NMR spectra were automatically reduced to ASCII files using the AMIX

430 software package (Analysis of Mixture, version 3.8, Bruker). Spectral intensities were scaled to the total  
431 spectral intensity, and the resulting data were analyzed by multivariate and univariate statistics. The  
432 NMR assignments were done using spectra online databases such as HMDB (<http://www.hmdb.ca>) and  
433 ChenomX NMR Suite (version 8.1 evaluation, ChenomX). The identification of succinate was carried  
434 out by supplementing a sample with exogenous succinate. Spectra analysis carried out with and without  
435 supplementation, allowed us to ensure signal specificity.

436 Non-supervised multivariate principal component analyses (PCA) were performed with data generated  
437 by <sup>1</sup>H-NMR (BAL) using SIMCA v14 software (Umetrics). The scores were plotted in 2D vs the two  
438 first principal components to visualize possible clusters. Succinate quantification in BAL and tracheal  
439 aspirates was performed using Metaboanalyst software ([www.metaboanalyst.ca](http://www.metaboanalyst.ca)).

440 ***Tracheal Aspirate collection.*** Aspirates were collected during routine tracheal suctioning of  
441 mechanically ventilated patients. Tracheal aspirate samples were collected from patients hospitalized at  
442 the University Hospital of Tours; 9 with influenza pneumonia and 7 not infected with influenza virus.  
443 Samples were dissociated in 3 volumes of PBS *per* gram, and 1 mM dithiothreitol, with stirring for 30  
444 min. After centrifugation at 500 g for 10 min, the supernatants were stored at -80°C until use.

445 ***Cytokine array and ELISA.*** Cytokine array and DuoSet ELISA (Human IL-6, IL-8/CXCL8,  
446 IP10/CXCL10, RANTES/CCL5 and mouse IL-6, KC, MPO) were performed according to the  
447 manufacturer's (R&D Systems) instructions.

448  
449 ***Cell culture.*** Experiments were performed using human bronchial epithelial BEAS-2B cells, except for  
450 live imaging which used human alveolar epithelial A549 cells, plaque assays which used Madin-Darby  
451 Canine Kidney (MDCK) cells and reverse genetics which used co-culture of MDCK and HEK-293T  
452 cells. All cells were mycoplasma-free, cultured in either F-12K Medium (BEAS-2B), **DMEM**  
453 **(16HBE14o-)** or MEM (A549, HEK-293T and MDCK) supplemented with 10% FBS and 100 U/mL  
454 penicillin, 100 µg/mL streptomycin. BEAS-2B cells were infected in medium without FBS for 4 hours  
455 with A/Scotland/20/74 (H3N2) IAV at MOI=1 (except for SEM analysis, for which an MOI=5 was  
456 applied, and in experiments using A/PR/8/34 (H1N1) wild-type and deltaNS1 viruses which used an

MOI=4). Cells were also stimulated in medium with FBS with 2 µg/mL of Poly (I:C). Four hours after the challenge, cells were washed with PBS and incubated for 4 h or 20 h with different concentrations of succinate or malonate, or with 10 nM of Leptomycin B. For multicycle replication analysis, BEAS-2B cells were infected with IAV at low MOI (*i.e* MOI=10<sup>-3</sup>) for 4h and treated or not with succinate for 20h. 2 µg/mL of TPCK-treated Trypsin were added simultaneously to succinate. Supernatants were centrifuged 5 min at 500 g and stored at -80°C for further analysis.

**Cell proliferation and cytotoxicity assays.** Cells in 96-well plates were washed twice with PBS and incubated for 1 h at 37°C with 100 µL of MTS reagent diluted 1/5 for the cell proliferation test. Optical density was measured at 490 nm. For the cytotoxicity assay, cells were stained for 15 min at 4°C with Live/Dead or with anti-Annexin V-FITC (1/20) and Propidium Iodide (1/100) before flow cytometry analysis.

**Microarrays.** Profiling of human bronchial epithelial BEAS-2B cells was performed using Agilent's SurePrint G3 human gene expression microarray kit. A single-color design provided two types of comparison: (i) IAV-infected *versus* mock-infected cells, and (ii) succinate-treated infected cells *versus* mock-infected cells. Cy3-labeled cRNAs were prepared from 100 ng of total RNA using a one-color Low Input Quick Amp labeling kit. Specific activities and cRNA yields were determined using a NanoDrop ND-1000 instrument. For each sample, 600 ng of Cy3-labeled cRNA (specific activity of >9 pmol Cy3/µg cRNA) was fragmented at 60°C for 30 min. cRNA was hybridized to the microarrays for 17 h at 65°C in a rotating hybridization oven as described previously (Barthelemy *et al*, 2018). After hybridization, microarrays were washed and then dried immediately. After washing, the slides were scanned using a G2565CA scanner system (Agilent Technologies), with a resolution of 3 µm and a 20-bit dynamic range. The resulting TIFF images were analyzed with Feature Extraction Software, using a GE1\_107\_Sep09 protocol. Identification of differentially expressed genes and functional investigations were done using GeneSpring software. Differentially expressed genes were identified using a moderated t test, and a P value cutoff of 5% was applied. A fold change cutoff of >2 was added to select genes expressed differentially between control and treated/infected

conditions. For further analysis, data files were uploaded into the Ingenuity Pathways Analysis (IPA) software (Ingenuity Systems). The right-tailed Fisher's exact test was used to calculate a P value for the probability that each canonical pathway assigned to that data set is due to chance alone.

**SeaHorse.** Cellular oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) data were obtained using a Seahorse XF96 flux analyzer from Seahorse Bioscience (Agilent Technologies) as we described previously (Kouzi *et al*, 2020). Experiments were performed according to the manufacturer's instructions. Briefly, bronchial epithelial BEAS-2B cells were seeded in XF96 cell culture plates at 30,000 cells *per* well and cultured overnight, then cells were infected with IAV for 18 h in the presence or absence of succinate. On the day of analysis, culture media were replaced with XF Base medium supplemented with glutamine (2 mM) and lacking bicarbonate (pH 7.4). Cells were then incubated at 37°C in a non-CO<sub>2</sub> incubator for 1 h and measurements were performed as described in the figure legends. Sequential injection of glucose (10 mM), oligomycin (1 µM), dinitrophenol (DNP) (100 µM) and rotenone/ antimycin A (0.5 µM) were added according to the suppliers' technical specifications and these permitted the determination of the main respiratory and glycolytic parameters. Data were acquired with the Seahorse Wave Controller and analyzed with Seahorse Wave Desktop Softwares.

**Neuraminidase (NA) assay.** The assay is based on the release of a 4-methylumbelliferone fluorescent product from the 2'-(4-Methylumbelliferyl)- $\alpha$ -D-N-acetylneuraminic acid sodium salt hydrate (MU-NANA) substrate as a measure of NA activity. 67 µL of cell supernatant was incubated with 33 µL of MU-NANA (50 µM) in black 96-well micro-plates. Fluorescence was immediately measured in a kinetic assay over 1 h at Ex = 355 nm and Em = 460 nm.

**IAV titration by plaque-forming units assay.** Titrations in cell supernatants, BALs and mouse lungs were performed as previously described (Blanc *et al*, 2016).

**Transmission and Scanning Electron Microscopy.** Cells were washed with PBS, detached using trypsin and centrifuged. Cells were fixed by incubation for 24 h in 4% paraformaldehyde, 1%

glutaraldehyde in 0.1 M phosphate buffer (pH 7.2). Samples were further washed in PBS and post-fixed by incubation with 2% osmium tetroxide for 1 h. Next, samples were fully dehydrated in a graded series of ethanol solutions and propylene oxide. An impregnation step was performed with a mixture of (1:1) propylene oxide/Epon resin and then samples were left overnight in pure resin. They were further embedded in Epon resin for 48 h at 60°C. Ultra-thin sections (90 nm) of these blocks were obtained using a Leica EM UC7 ultramicrotome (Wetzlar, Germany). Sections were stained with 2% uranyl acetate and 5% lead citrate. Observations were made with a transmission electron microscope (JEOL 1011) and analyzed with a Digital Micrograph.

For scanning electron microscopy, samples were fully dehydrated in a graded series of ethanol solutions and dried in hexamethyldisilazane (HMDS, Sigma, St-Louis, MO). Dried samples were sprinkled onto carbon disks and coated with 40 Å platinum, with a GATAN PECS 682 apparatus (Pleasanton, CA), before observation under a Zeiss Ultra plus FEG-SEM scanning electron microscope (Oberkochen, Germany). IAV particles were colored in pink by digital computer processing.

**Western-blotting.** Cells in 6-well plates were lysed with 150 µL of RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, 1 mM ethylenediaminetetraacetic acid, 1% Triton X100, 1% sodium deoxycholic acid, 0.1% sodium dodecyl sulphate) and a protease inhibitor cocktail (diluted 1/200). Samples were centrifuged for 15 min at 12,000 g to eliminate debris, then protein concentrations were measured using a Pierce<sup>TM</sup> Protein BCA Assay Kit. Ten µg of total proteins were diluted with reducing or non-reducing Laemmli buffer, heated at 100°C for 5 min, then loaded onto 4/12% SDS-PAGE. Proteins were subsequently transferred to nitrocellulose membranes, and probed with anti-NP (1/500), anti-NS1 (1/1000), anti-PA (1/1000), anti-PB2 (1/500), anti-M1 (1/1000), anti-M2 (1/1000), anti-CRM1 (1/500) or anti-β-actin (1/5000). Bound antibodies were revealed with an anti-rabbit IgG for NS1 and PB2 and anti-mouse IgG for other proteins (HRP linked) and ECL detection reagents. An automated imaging system (MF ChemiBis 3.2, DNR BioImaging Systems) was used for detection, and the FUJI FILM MultiGauge software was subsequently used for analysis and quantification.

536

537 ***RNA isolation and RT-qPCR.*** Cells in 6-well plates were lysed with 350  $\mu$ L of “RA1” buffer  
538 (included in the Macherey-Nagel RNA extraction kit) and  $\beta$ -mercaptoethanol diluted 1/100. Total  
539 RNAs from cells or from purified A/Scotland/20/74 (H3N2) IAV were extracted using the  
540 NucleoSpin® RNA kit, including a step of genomic DNA digestion with DNase. Nucleic samples  
541 were quantified using a Nanodrop 2000 UV-visible spectrophotometer. Single-stranded cDNA was  
542 synthesized from 500 ng total RNA for each sample with the High Capacity cDNA reverse  
543 transcription kit (Applied Biosystems), using the specific sense IAV M1 primer (5'-TCT AAC CGA  
544 GGT CGA AAC GTA-3'). mRNA levels were determined using quantitative real-time PCR with a  
545 LightCycler 480 instrument (Roche Diagnostics). PCR was carried out using 10 ng of reverse-  
546 transcribed total RNA as the template, 10  $\mu$ M (each) forward and reverse primers (sense: 5'-AAG  
547 ACC AAT CCT GTC ACC TCT GA-3'; antisense: 5'-CAA AGC GTC TAC GCT GCA GTC C-3'),  
548 and 10  $\mu$ L SYBR® Premix Ex Taq in a final volume of 20  $\mu$ L. Each reaction was performed in  
549 duplicate in white 96-well plates. The thermal protocol consisted of an initial denaturation step at  
550 95°C for 30 s followed by 40 cycles of denaturation at 95°C for 5 s and primer annealing and  
551 extension at 60°C for 20 s (reading at 83°C). Melting curves were generated for each amplified  
552 cDNA to check the reaction specificity. For quantification analyses, serial dilutions of IAV cDNA  
553 (from 40 ng to 0.5 ng cDNA) were used to create a standard curve.

554

555 ***Flow cytometry analysis.*** BAL were dispensed into round bottomed 96-well plates and were  
556 centrifuged at 300 *g* at 4°C for 5 min. One well was seeded for each of the following controls:  
557 unstained cells, single-stained cells, isotype controls. Samples were further stained using specific  
558 antibodies and appropriate isotype controls as listed in the supplementary table.

559 **Adherent epithelial cells were removed from their substrate by treatment with Trypsin a few minutes at**  
560 **37°C. Trypsin was inhibited by adding 800  $\mu$ L of culture media and cells were centrifugated at 500 *g***  
561 **for 5 min. Cell pellet was re-suspended in staining buffer (50 mM EDTA, 5% FCS in PBS), dispensed**  
562 **into round bottomed 96-well plates (100 000 cells in 100  $\mu$ L), and were then centrifuged at 300 *g* at 4**  
563 **°C for 5 min. For nucleoprotein staining, cells were permeabilized with the Cytofix/Cytoperm™**



Solution Kit or True Nuclear<sup>TM</sup> Transcription Factor Buffer Set, following manufacturer's instructions. Samples were further incubated for 1h at 4 °C with anti-NP-FITC antibody diluted 1/300e or isotype control. Flow cytometry data were acquired on a MACSQuant® Analyzer and analyses were performed using the VenturiOne software.

**Histopathology.** Lungs were collected immediately after euthanasia and airways were washed and placed in 4% paraformaldehyde in PBS. Lung sections of approximately 4 µm thickness were cut and stained with hematoxylin-eosin. A study pathologist examined the tissue sections using light microscopy on a Leica Diaplan microscope in a blinded experimental protocol. All histopathological findings were graded in a semi-quantitative fashion on a scale of 0 to 4 (0: absent, 1: mild, 2: moderate, 3: severe, 4: extremely severe). All lung preparations and analyses were performed at the LAPV (Amboise, France).

**Generation of recombinant fluorescent IAV and time-lapse imaging.** The 8 plasmid reverse genetics system (Hoffmann *et al*, 2002) was used to generate a recombinant virus expressing an eGFP reporter protein fused to the NS1 protein of the influenza A/WSN/33 (H1N1) virus. The NS1-eGFP-WSN virus was rescued using a previously described procedure (Vidy *et al*, 2016) and was propagated in MDCK cells. For long term time-lapse microscopy, A549 cells grown on cell culture in micro-wells were infected with NS1-eGFP-WSN at an MOI of 0.5 pfu/cell. Pictures were taken every 10 min starting at 1 h post-infection and continuing until 24 h post-infection, on a Nikon BioStation microscope using BioStation IM software. The intensity of the GFP associated fluorescence *per* infected cell was quantified using Image J software.

**Confocal fluorescence microscopy.** Cells were grown in 12-well plates with a cover slide in the bottom of the well. After different treatments, cells were fixed using 4% formaldehyde for 30 min at room temperature and then permeabilized in PBS 0.1% Triton X-100 for 30 min at room temperature. Following a 1 h saturation step with PBS 1% bovine serum albumin, 0.1% Tween 20, cells were stained for 2 h at room temperature with the following antibodies: anti-NP-FITC (1/30), anti-NS1 (1/200), anti-M2 (1/150), anti-M1 (1/150), anti-PA (1/50), anti-PB2 (1/200), anti-NEP/NS2 (1/100) or anti-NP mAb clone 3/1 (1/1000). An anti-rabbit-AF488 was used for 2 h at room temperature as

the secondary antibody for NS1, NEP/NS2 and PB2, and an anti-mouse-AF488 was used for other proteins. Then actin was stained with ActinRed 555 reagent for 30 min and nuclei were stained with the NucBlue reagent for 5 min. Samples were analyzed with a Leica SP8 confocal microscope and Leica LasX Life Sciences Software. Relative nuclear intensity was determined by using the Intensity Ratio Nuclei Cytoplasm Tool, RRID:SCR\_018573).

***Succinylation analysis by LC-MS/MS.*** Human bronchial epithelial BEAS-2B cells were grown in 10 culture dishes (150 mm) *per* condition. After different treatments, cells were washed with 5 mL of cold PBS, then lysed with 5 mL of urea buffer (8 M urea, 200 mM ammonium bicarbonate). The lysates were clarified by centrifugation at 12,000 *g* for 15 min at 4°C. Protein concentrations were measured with a Nano Drop spectrophotometer to take samples corresponding to 8 mg of proteins. Reduction and alkylation of proteins were performed by incubation for 1 h at 37°C with 10 mL of DTT 10 mM (5mM final) and then 30 min at room temperature with 4 mL of iodoacetamide 55 mM (10 mM final). After addition of 20 mL ammonium bicarbonate 200 mM, proteins were digested for 2 h at 37°C with Trypsin/LysC diluted 1/1000. 800 µL of TPCK-trypsin at 1 mg/mL were added and the samples were incubated overnight at 37°C. Five mL of 50% formic acid was added to allow purification of peptides over Sep-Pak® C<sub>18</sub> columns. Briefly, columns were equilibrated with 3x2 mL of 70% ACN + 0.1% formic acid and were washed with 3x2 mL of 0.1% formic acid. Samples were loaded, and columns washed as previously. Elution was done with 6 mL 40% ACN + 0.1% formic acid. Eluates were frozen (-80°C) overnight and lyophilized. Immunoaffinity purification of succinylated peptides was performed with a PTMScan® Succinyl-Lysine Motif kit according to the manufacturer's instructions. Immuno-isolate peptide samples were then loaded onto a homemade C18 StageTip for desalting. Peptides were eluted using 40/60 MeCN/H<sub>2</sub>O + 0.1% formic acid and vacuum concentrated to dryness before being reconstituted in injection buffer (2% MeCN/ 0.3% TFA) for nano-LC-MS/MS analysis. Liquid chromatography (LC) was performed with an RSLCnano system (Ultimate 3000, Thermo Scientific) coupled online to an Orbitrap Exploris<sup>TM</sup> 480 mass spectrometer (Thermo Scientific). Peptides were trapped on a C18 Nano Trap column with buffer A (2/ 98 MeCN/ H<sub>2</sub>O in 0.1% formic acid) at a flow rate of 3.0 µL/min over 4 min. Separation was performed on a C18 Acclaim PepMap<sup>TM</sup> RSLC column

regulated to a temperature of 50°C with a linear gradient of 2% to 25% buffer B (100% MeCN in 0.1% formic acid) at a flow rate of 300 nL/min over 91 min. MS full scans were performed in the ultrahigh-field Orbitrap mass analyzer in m/z ranges of 375–1500 with a resolution of 120,000 at m/z 200. The top 25 most intense ions were subjected to Orbitrap for further fragmentation via high energy collision dissociation (HCD) activation and a resolution of 15,000 with the AGC target set to 100%. We selected ions with charge state from 2<sup>+</sup> to 6<sup>+</sup> for screening. Normalized collision energy (NCE) was set at 30 and the dynamic exclusion was 45 s. Mass spectrometry proteomics raw data have been deposited with the ProteomeXchange Consortium via the PRIDE (Perez-Riverol *et al*, 2019) partner repository with the dataset identifier PXD018419 (username: reviewer53974@ebi.ac.uk, password: hTdy0ILL). For identification, the data were searched against the *Homo Sapiens* (UP000005640) and the *influenza A virus* (UP000162741) UniProt databases using Sequest-HT through proteome discoverer (version 2.2 or 2.4). Enzyme specificity was set to trypsin and a maximum of three-missed cleavages sites were allowed. Oxidized methionine, N-terminal acetylation, Succinyl-Lysine and carbamidomethyl cysteine were set as variable modifications. The maximum mass deviation allowed was set to 10 ppm for monoisotopic precursor ions and 0.02 Da for MS/MS peaks. The resulting files were further processed using myProMS (Poullet *et al*, 2007). FDR calculation employed Percolator and was set to 1% at the peptide level for the whole study. To quantify the succinylated peptide that contained lysine K87, we extracted from the MS survey of the nano-LC-MS/MS raw files the ion chromatogram (XIC) signal using the retention time and m/z values of the well-characterized tryptic peptide ions using the Xcalibur softwares (manually). XIC areas were integrated in Xcalibur under the QualBrowser interface using the ICIS algorithm. Boxplots were constructed from two sets of three independent experiments (IAV and IAV + Succinate). Thus, three data points were used for each box. The whiskers correspond to the minimum and maximum values, while the last point is the median. The first and third quartiles are merely the average values between the median and the extrema. It should be noted that boxplots do not indicate actual distributions (there are no values inside a box, except the median), but rather they are used to show different tendencies between two conditions.

**Fluorescence anisotropy measurements.** The full-length influenza virus NP (strain A/WSN/1933) gene, cloned in pET22b (Novagen), was used. The point mutation that gives the K87 > E change was introduced by PCR, by site directed mutagenesis and full-plasmid amplification, followed by DpnI restriction digestion. Sequencing was done by Eurofins Genomics. Production in *Escherichia coli* BL21 RIL (DE3) cells and purification of wild-type NP and K87E were carried out as previously described (Chenavas *et al*, 2013; Labaronne *et al*, 2016). Fluorescence anisotropy measurements were done in a 384-well microplate, and acquisitions were performed at room temperature after a 5 min incubation on a Clariostar plate reader (BMG Labtech) with polarization filters. NP was serially diluted in buffer (20 mM Tris-HCl pH 7.5, 150 mM NaCl and 5 mM  $\beta$ -mercaptoethanol) and titrated into 5 nM polyUC RNA (Integrated DNA Technologies) 3'-labelled with 6-fluorescein (FAM). After blank subtraction of the RNA alone, a triplicate of each titration was fitted to the Prism (GraphPad) binding equation "Single binding site with Hill slope (h)".

**Reverse genetics.** 500 ng of each of the 8 bidirectional pRF483 plasmids encoding all the genomic segments of the A/Scotland/20/74 (H3N2) virus were transfected by LTX lipofectamine (Invitrogen) in a mix of HEK293T and MDCK cells. The reconstitution of viruses with an NP bearing either the wild-type K87, the K87R or the K87E mutations was performed in parallel. Negative controls of each virus were also prepared by transfection of cells with all genomic-encoding plasmids, with the exception of the PB1 expression plasmid. After 24 h, the cells were washed and incubated for 48 h in MEM medium supplemented with 1  $\mu$ g/mL of trypsin-TPCK. The viruses released were further amplified in MDCK cells in MEM medium supplemented with 1  $\mu$ g/mL of trypsin-TPCK and titrated after 72 h. NP sequence of rescued viruses (K87 and K87R) were verified by sequencing using the following primers (sense: 5'-ATG GCG TCC CAA GGC-3'; antisense: 5'-TTA ATT GTC GTA CTC CTC TGC-3'; Eurofins Genomics)).

**Statistical analysis.** Sample size estimate for animal studies were based on the experience of our group on IAV-infected mice model. There was no randomization or blinding procedure. Sample size for the human investigation could not be calculated because of the exploratory nature of this research but it was

estimated according to previous studies with a similar design (Guillon *et al*, 2019, 2015, 2016). Statistical analyses were performed using GraphPad Prism. Data are reported as mean  $\pm$  SEM. Statistical values, including the number of replicates (n) and the statistical test used, can be found in the figure legends. \*p < 0.05, \*\*p < 0.005, \*\*\*p < 0.0005, \*\*\*\*p < 0.0001. For *in vitro* experiments, n = the number of separate experiments. For *in vivo* work, n = the number of individual animals.

**Study approvals.** All animal experimentations were performed according to the ethical guidelines and were approved by our local and national ethics committee (CEEA.19, #201604071220401-4885). Study of human samples was approved by the IRB of the Tours University Hospital/French national bioethics authority (CPP-37 2012-R21) (DC-2014-2285). Informed written consent was obtained from all subjects. The study was conformed to the principles set out in the VMA Declaration of Helsinki and the Department of Health and Human Service Belmont Report.

**Data Availability.** MIAME (minimum information about microarray experiment) compliant data were deposited in Array-Express at EMBL (access number: E-MTAB-10031). Succinylation data provided by LC-MS/MS were deposited in PRIDE (Project Name: Influenza A virus-triggered succinylation in lung epithelial cells; Project accession: PXD018419 (username: reviewer53974@ebi.ac.uk, password: hTdy0iLL)).

## CONTRIBUTIONS

**AG**, Conceptualization, Formal analysis, Supervision, Validation, Visualization, Writing - original draft; Writing - review & editing; **DD**, **AC**, Investigation, Methodology, Data curation, Formal analysis, Validation, Visualization; Writing - review & editing; **TB**, **JB**, **FP**, **VV**, **AW**, **LM**, **CC**, **LND**, **AA**, **FD**, **AT**, **ALG**, **FF**, **AD**, Investigation, Methodology, Validation ; review & editing; **JMC**, **TC**, **PSH**, **CP**, **DL**, **OH**, Formal analysis, Resources, Validation; review & editing; **NN**, **RLG**, Formal analysis, Resources, Supervision, Validation, Writing - review & editing; **MS-T** Conceptualization, Formal analysis, Funding acquisition, Supervision, Validation, Writing - original draft, Writing - review & editing, Project administration.

## FUNDING & ACKNOWLEDGMENTS

This work was partially supported by the following grants: Inserm, Université of Tours, Région Centre-Val de Loire FLU-MET#2018-00124196, VLM#RF2018052289 (to M.S.-T.); FEDER Euro-FERI (to M.S.-T. and C.P.), Studium research fellowship (to P.S.H. and M.S.-T.), SIRIC Montpellier Cancer Grant INCa\_Inserm\_DGOS\_12553 (to A.T.); LabEx IBEID Grant No. 10-LABX-0062 (to N.N.); Ph.D. fellowship from INRAe - Department of animal health (to L.M.). This work used the platforms of the Grenoble Instruct-ERIC center (ISBG; UMS 3518 CNRS-CEA-UGA-EMBL) within the Grenoble Partnership for Structural Biology (PSB), supported by FRISBI (ANR-10-INBS-05-02) and GRAL, financed by the University Grenoble Alpes - Ecoles Universitaires de Recherche CBH-EUR-GS (ANR-17-EURE-0003).

The authors are very grateful to Dr Evgenia Turtoi (Université de Montpellier, France) for LC-MS metabolomic analyses, sample preparations and measurements, to Dr. Bruno Da Costa (VIM, INRAe, Jouy-en-Josas, France) for his contribution to the production of wild-type and mutant influenza viruses by reverse genetics and to Pr. Rob WH Ruigrok (IBS, Grenoble, France) for fruitful discussions. We also thank Dr Richard Webby (St. Jude Children's Research Hospital, Memphis, USA) and Dr Daniel Marc (INRAe, Nouzilly, France) for their generous gifts of the mAb 3/1 antibody and the polyclonal anti-NS1 antibody, respectively, and Dr Georg Kochs (Freiburg University) for kindly providing the

715 A/PR/8/34 wild-type and ΔNS1 viruses. The authors would like to thank the Animal Facility of the  
716 University of Tours, the study nurses and all the physicians of the Critical Care Section of Tours  
717 University Hospital, for their assistance. We are also grateful to all patients who volunteered for this  
718 study.

719

720 **DISCLOSURE STATEMENT & COMPETING INTERESTS:**

721 M.S.-T. holds a French national research agency grant (ANR-21-CE18-0061-01, which started January  
722 2022) to develop a succinate-based therapy against influenza virus infection. The other authors declare  
723 that they have no conflict of interest.

## REFERENCES

- Bahadoran A, Bezavada L & Smallwood HS (2020) Fueling influenza and the immune response: Implications for metabolic reprogramming during influenza infection and immunometabolism. *Immunol Rev* 295: 140–166
- Barthelemy A, Sencio V, Soulard D, Deruyter L, Faveeuw C, Le Goffic R & Trottein F (2018) Interleukin-22 Immunotherapy during Severe Influenza Enhances Lung Tissue Integrity and Reduces Secondary Bacterial Systemic Invasion. *Infect Immun* 86
- Blanc F, Furio L, Moisy D, Yen H-L, Chignard M, Letavernier E, Naffakh N, Mok CKP & Si-Tahar M (2016) Targeting host calpain proteases decreases influenza A virus infection. *Am J Physiol Lung Cell Mol Physiol* 310: L689-699
- Bolte H, Rosu ME, Hagelauer E, García-Sastre A & Schwemmle M (2019) Packaging of the Influenza Virus Genome Is Governed by a Plastic Network of RNA- and Nucleoprotein-Mediated Interactions. *J Virol* 93
- Chandler JD, Hu X, Ko E-J, Park S, Lee Y-T, Orr M, Fernandes J, Uppal K, Kang S-M, Jones DP, *et al* (2016) Metabolic pathways of lung inflammation revealed by high-resolution metabolomics (HRM) of H1N1 influenza virus infection in mice. *Am J Physiol Regul Integr Comp Physiol* 311: R906–R916
- Chenavas S, Estrozi LF, Slama-Schwok A, Delmas B, Di Primo C, Baudin F, Li X, Crépin T & Ruigrok RWH (2013) Monomeric nucleoprotein of influenza A virus. *PLoS Pathog* 9: e1003275
- Connors J, Dawe N & Van Limbergen J (2018) The Role of Succinate in the Regulation of Intestinal Inflammation. *Nutrients* 11
- Cui L, Zheng D, Lee YH, Chan TK, Kumar Y, Ho WE, Chen JZ, Tannenbaum SR & Ong CN (2016a) Metabolomics Investigation Reveals Metabolite Mediators Associated with Acute Lung Injury and Repair in a Murine Model of Influenza Pneumonia. *Sci Rep* 6: 26076
- Cui Z, Ojaghian MR, Tao Z, Kakar KU, Zeng J, Zhao W, Duan Y, Vera Cruz CM, Li B, Zhu B, *et al* (2016b) Multiplex PCR assay for simultaneous detection of six major bacterial pathogens of rice. *J Appl Microbiol* 120: 1357–1367
- Denney L & Ho L-P (2018) The role of respiratory epithelium in host defence against influenza virus infection. *Biomed J* 41: 218–233
- Dou D, Revol R, Östbye H, Wang H & Daniels R (2018) Influenza A Virus Cell Entry, Replication, Virion Assembly and Movement. *Front Immunol* 9: 158
- Duwe S. Influenza viruses - antiviral therapy and resistance. (2017) *GMS Infect Dis.* 2017 5:Doc04.



760 Eisenreich W, Rudel T, Heesemann J & Goebel W (2019) How Viral and Intracellular  
761 Bacterial Pathogens Reprogram the Metabolism of Host Cells to Allow Their  
762 Intracellular Replication. *Front Cell Infect Microbiol* 9: 42

763 Einfeld AJ, Kawakami E, Watanabe T, Neumann G & Kawaoka Y (2011) RAB11A is  
764 essential for transport of the influenza virus genome to the plasma membrane. *J Virol*  
765 85: 6117–6126

766 Elton D, Medcalf E, Bishop K & Digard P (1999) Oligomerization of the influenza virus  
767 nucleoprotein: identification of positive and negative sequence elements. *Virology*  
768 260: 190–200

769 Elton D, Simpson-Holley M, Archer K, Medcalf L, Hallam R, McCauley J & Digard P (2001)  
770 Interaction of the influenza virus nucleoprotein with the cellular CRM1-mediated  
771 nuclear export pathway. *J Virol* 75: 408–419

772 Graham LS, Krass L, Zariffard MR, Spear GT & Mirmonsef P (2013) Effects of Succinic  
773 Acid and Other Microbial Fermentation Products on HIV Expression in Macrophages.  
774 *BioResearch Open Access* 2: 385–391

775 Gregory DJ & Kobzik L (2015) Influenza lung injury: mechanisms and therapeutic  
776 opportunities. *Am J Physiol Lung Cell Mol Physiol* 309: L1041-1046

777 Grimolizzi F & Arranz L (2018) Multiple faces of succinate beyond metabolism in blood.  
778 *Haematologica* 103: 1586–1592

779 Guillon A, Brea D, Luczka E, Hervé V, Hasanat S, Thorey C, Pérez-Cruz M, Hordeaux J,  
780 Mankikian J, Gosset P, *et al* (2019) Inactivation of the interleukin-22 pathway in the  
781 airways of cystic fibrosis patients. *Cytokine* 113: 470–474

782 Guillon A, Brea D, Morello E, Tang A, Jouan Y, Ramphal R, Korkmaz B, Perez-Cruz M,  
783 Trottein F, O’Callaghan RJ, *et al* (2016) *Pseudomonas aeruginosa* proteolytically  
784 alters the interleukin 22-dependent lung mucosal defense. *Virulence*: 1–11

785 Guillon A, Jouan Y, Brea D, Gueugnon F, Dalloneau E, Baranek T, Henry C, Morello E,  
786 Renaud J-C, Pichavant M, *et al* (2015) Neutrophil proteases alter the interleukin-22-  
787 receptor-dependent lung antimicrobial defence. *Eur Respir J* 46: 771–782

788 Guillot L, Le Goffic R, Bloch S, Escriou N, Akira S, Chignard M & Si-Tahar M (2005)  
789 Involvement of toll-like receptor 3 in the immune response of lung epithelial cells to  
790 double-stranded RNA and influenza A virus. *J Biol Chem* 280: 5571–5580

791 Hoffmann E, Krauss S, Perez D, Webby R & Webster RG (2002) Eight-plasmid system for  
792 rapid generation of influenza virus vaccines. *Vaccine* 20: 3165–3170

793 Hu J, Zhang L & Liu X (2020) Role of Post-translational Modifications in Influenza A Virus  
794 Life Cycle and Host Innate Immune Response. *Front Microbiol.* 11:517461.

795 Infantino V, Pierri CL & Iacobazzi V (2019) Metabolic Routes in Inflammation: The Citrate  
796 Pathway and its Potential as Therapeutic Target. *Curr Med Chem* 26: 7104–7116

797 Jang YH, Seong BL. (2019) The Quest for a Truly Universal Influenza Vaccine. *Front Cell*  
798 *Infect Microbiol.* 9:344.

799 Jefferson T, Jones MA, Doshi P, Del Mar CB, Hama R, Thompson MJ, Spencer EA,  
800 Onakpoya I, Mahtani KR, Nunan D, *et al* (2014) Neuraminidase inhibitors for  
801 preventing and treating influenza in healthy adults and children. *Cochrane Database*  
802 *Syst Rev*: CD008965

803 Jha AK, Huang SC-C, Sergushichev A, Lampropoulou V, Ivanova Y, Loginicheva E,  
804 Chmielewski K, Stewart KM, Ashall J, Everts B, *et al* (2015) Network integration of  
805 parallel metabolic and transcriptional data reveals metabolic modules that regulate  
806 macrophage polarization. *Immunity* 42: 419–430

807 Kakisaka M, Yamada K, Yamaji-Hasegawa A, Kobayashi T & Aida Y (2016) Intrinsically  
808 disordered region of influenza A NP regulates viral genome packaging via interactions  
809 with viral RNA and host PI(4,5)P2. *Virology* 496: 116–126

810 Keiran N, Ceperuelo-Mallafre V, Calvo E, Hernández-Alvarez MI, Ejarque M, Núñez-Roa C,  
811 Horrillo D, Maymó-Masip E, Rodríguez MM, Fradera R, *et al* (2019) SUCNR1  
812 controls an anti-inflammatory program in macrophages to regulate the metabolic  
813 response to obesity. *Nat Immunol* 20: 581–592

814 Keshavarz M, Solaymani-Mohammadi F, Namdari H, Arjeini Y, Mousavi MJ & Rezaei F  
815 (2020) Metabolic host response and therapeutic approaches to influenza infection. *Cell*  
816 *Mol Biol Lett* 25: 15

817 Kouzi F, Zibara K, Bourgeais J, Picou F, Gallay N, Brossaud J, Dakik H, Roux B, Hamard S,  
818 Le Nail LR, *et al* (2020) Disruption of gap junctions attenuates acute myeloid  
819 leukemia chemoresistance induced by bone marrow mesenchymal stromal cells.  
820 *Oncogene* 39: 1198–1212

821 Kudo N, Matsumori N, Taoka H, Fujiwara D, Schreiner EP, Wolff B, Yoshida M &  
822 Horinouchi S (1999) Leptomycin B inactivates CRM1/exportin 1 by covalent  
823 modification at a cysteine residue in the central conserved region. *Proc Natl Acad Sci*  
824 *U S A* 96: 9112–9117

825 Kudo N, Wolff B, Sekimoto T, Schreiner EP, Yoneda Y, Yanagida M, Horinouchi S &  
826 Yoshida M (1998) Leptomycin B inhibition of signal-mediated nuclear export by  
827 direct binding to CRM1. *Exp Cell Res* 242: 540–547

828 Labaronne A, Swale C, Monod A, Schoehn G, Crépin T & Ruigrok RWH (2016) Binding of  
829 RNA by the Nucleoproteins of Influenza Viruses A and B. *Viruses* 8: 247.

830 Lampejo T. (2020) Influenza and antiviral resistance: an overview. *Eur J Clin Microbiol*  
831 *Infect Dis.* 39: 1201-1208.

832 Le Goffic R, Balloy V, Lagranderie M, Alexopoulou L, Escriou N, Flavell R, Chignard M &  
833 Si-Tahar M (2006) Detrimental contribution of the Toll-like receptor (TLR)3 to  
834 influenza A virus-induced acute pneumonia. *PLoS Pathog* 2: e53

835 Littlewood-Evans A, Sarret S, Apfel V, Loesle P, Dawson J, Zhang J, Muller A, Tigani B,  
836 Kneuer R, Patel S, *et al* (2016) GPR91 senses extracellular succinate released from

837 inflammatory macrophages and exacerbates rheumatoid arthritis. *J Exp Med* 213:  
838 1655–1662

839 Mills EL, Kelly B, Logan A, Costa ASH, Varma M, Bryant CE, Tourlomousis P, Däbritz  
840 JHM, Gottlieb E, Latorre I, *et al* (2016) Succinate Dehydrogenase Supports Metabolic  
841 Repurposing of Mitochondria to Drive Inflammatory Macrophages. *Cell* 167: 457-  
842 470.e13

843 Moreira ÉA, Weber A, Bolte H, Kolesnikova L, Giese S, Lakdawala S, Beer M, Zimmer G,  
844 García-Sastre A, Schwemmle M, *et al* (2016) A conserved influenza A virus  
845 nucleoprotein code controls specific viral genome packaging. *Nat Commun* 7: 12861

846 Murphy MP & O'Neill LAJ (2018) Krebs Cycle Reimagined: The Emerging Roles of  
847 Succinate and Itaconate as Signal Transducers. *Cell* 174: 780–784

848 Park J, Chen Y, Tishkoff DX, Peng C, Tan M, Dai L, Xie Z, Zhang Y, Zwaans BMM,  
849 Skinner ME, *et al* (2013) SIRT5-mediated lysine desuccinylation impacts diverse  
850 metabolic pathways. *Mol Cell* 50: 919–930

851 Pearce EJ & Pearce EL (2018) Immunometabolism in 2017: Driving immunity: all roads lead  
852 to metabolism. *Nat Rev Immunol* 18: 81–82

853 Perez-Riverol Y, Csordas A, Bai J, Bernal-Llinares M, Hewapathirana S, Kundu DJ, Inuganti  
854 A, Griss J, Mayer G, Eisenacher M, *et al* (2019) The PRIDE database and related tools  
855 and resources in 2019: improving support for quantification data. *Nucleic Acids Res*  
856 47: D442–D450

857 Pizzorno A, Padey B, Terrier O & Rosa-Calatrava M (2019) Drug Repurposing Approaches  
858 for the Treatment of Influenza Viral Infection: Reviving Old Drugs to Fight Against a  
859 Long-Lived Enemy. *Front Immunol* 10

860 Potter VR & Dubois KP (1943) STUDIES ON THE MECHANISM OF HYDROGEN  
861 TRANSPORT IN ANIMAL TISSUES : VI. INHIBITOR STUDIES WITH  
862 SUCCINIC DEHYDROGENASE. *J Gen Physiol* 26: 391–404

863 Pouillet P, Carpentier S & Barillot E (2007) myProMS, a web server for management and  
864 validation of mass spectrometry-based proteomic data. *Proteomics* 7: 2553–2556

865 Rambold AS & Pearce EL (2018) Mitochondrial Dynamics at the Interface of Immune Cell  
866 Metabolism and Function. *Trends Immunol* 39: 6–18

867 Rubic T, Lametschwandtner G, Jost S, Hinteregger S, Kund J, Carballido-Perrig N,  
868 Schwärzler C, Junt T, Voshol H, Meingassner JG, *et al* (2008) Triggering the  
869 succinate receptor GPR91 on dendritic cells enhances immunity. *Nat Immunol* 9:  
870 1261–1269

871 Ryan DG, Murphy MP, Frezza C, Prag HA, Chouchani ET, O'Neill LA & Mills EL (2019)  
872 Coupling Krebs cycle metabolites to signalling in immunity and cancer. *Nat Metab* 1:  
873 16–33

874 Simmons C & Farrar J (2008) Insights into inflammation and influenza. *N Engl J Med* 359:  
875 1621–1623

876 Si-Tahar M, Touqui L & Chignard M (2009) Innate immunity and inflammation--two facets  
877 of the same anti-infectious reaction. *Clin Exp Immunol* 156: 194–198

878 Smallwood HS, Duan S, Morfouace M, Rezinciuc S, Shulkin BL, Shelat A, Zink EE, Milasta  
879 S, Bajracharya R, Oluwaseun AJ, *et al* (2017) Targeting Metabolic Reprogramming  
880 by Influenza Infection for Therapeutic Intervention. *Cell Rep* 19: 1640–1653

881 Tang Y-S, Xu S, Chen Y-W, Wang J-H & Shaw P-C (2021) Crystal structures of influenza  
882 nucleoprotein complexed with nucleic acid provide insights into the mechanism of  
883 RNA interaction. *Nucleic Acids Res* 49: 4144–4154

884 Tannahill GM, Curtis AM, Adamik J, Palsson-McDermott EM, McGettrick AF, Goel G,  
885 Frezza C, Bernard NJ, Kelly B, Foley NH, *et al* (2013) Succinate is an inflammatory  
886 signal that induces IL-1 $\beta$  through HIF-1 $\alpha$ . *Nature* 496: 238–242

887 Taubenberger JK, Kash JC, Morens DM. (2019) The 1918 influenza pandemic: 100 years of  
888 questions answered and unanswered. *Sci Transl Med.* 11(502): eaau5485

889 Tian X, Zhang K, Min J, Chen C, Cao Y, Ding C, Liu W & Li J (2019) Metabolomic  
890 Analysis of Influenza A Virus A/WSN/1933 (H1N1) Infected A549 Cells during First  
891 Cycle of Viral Replication. *Viruses* 11

892 Vidy A, Maisonnasse P, Da Costa B, Delmas B, Chevalier C & Le Goffic R (2016) The  
893 Influenza Virus Protein PB1-F2 Increases Viral Pathogenesis through Neutrophil  
894 Recruitment and NK Cells Inhibition. *PloS One* 11: e0165361

895 Wendt CH, Castro-Pearson S, Proper J, Pett S, Griffin TJ, Kan V, Carbone J, Koulouris N,  
896 Reilly C, Neaton JD, *et al* (2021) Metabolite profiles associated with disease  
897 progression in influenza infection. *PloS One* 16: e0247493

898 WHO | WHO guidelines for pharmacological management of pandemic (H1N1) 2009  
899 influenza and other influenza viruses *WHO*

900 Williams NC & O'Neill LAJ (2018) A Role for the Krebs Cycle Intermediate Citrate in  
901 Metabolic Reprogramming in Innate Immunity and Inflammation. *Front Immunol* 9:  
902 141

903 Xie Z, Dai J, Dai L, Tan M, Cheng Z, Wu Y, Boeke JD & Zhao Y (2012) Lysine  
904 succinylation and lysine malonylation in histones. *Mol Cell Proteomics MCP* 11: 100–  
905 107

906 Yang Y & Gibson GE (2019) Succinylation Links Metabolism to Protein Functions.  
907 *Neurochem Res* 44: 2346–2359

908 Ye Q, Krug RM & Tao YJ (2006) The mechanism by which influenza A virus nucleoprotein  
909 forms oligomers and binds RNA. *Nature* 444: 1078–1082

910 Zaslona Z & O'Neill LAJ (2020) Cytokine-like Roles for Metabolites in Immunity. *Mol Cell*  
911 78: 814–823

912

## FIGURES LEGENDS

### Figure 1. Influenza virus infection increases succinate levels in airways.

(a) C57Bl/6 mice were infected (n=9) or not (n=8) intranasally with 150 pfu of influenza A virus (IAV; A/Scotland/20/74 (H3N2)). Bronchoalveolar lavage fluids (BALs) were collected 4 days post-infection. Samples were further processed for metabolomic analysis by NMR. *Left panel* shows a volcano-plot representing the comparison of “IAV-infected” *versus* “control, non-infected” animals. The graph plots the  $-\log(p\text{-value})$  against the fold change ( $\log_2(\text{ratio})$ ) for individual metabolites. Vertical dashed blue lines mark the two-fold change and horizontal dashed blue line marks the cut-off p-value of 0.0001. Metabolites in the upper right square in red are significantly more abundant in “IAV-infected” compared to “control, non-infected” samples. Succinate is one of these compounds with a FC=2.2 and a FDR-adjusted p-value=8.10<sup>-7</sup>. The boxplots whiskers correspond to the minimum and maximum values, while the central band is the mean. The first and third quartiles (boxes) are merely the average values between the median and the extrema.

(b) shows succinate quantification by NMR from tracheal aspirates collected in mechanically-ventilated patients with (pink bar, n=9) or without (orange bar, n=7) diagnostic of IAV pneumonia. \* $P < 0.05$ .

(c) IL-6 and IL-8 measurements by ELISA from these same tracheal aspirates.

(d) Main baseline characteristics of the patients included in the study.

Data information: Data are mean  $\pm$  SEM and statistical analysis was performed using the Mann-Whitney U-test.

### Figure 2. Succinate reverses the inflammatory response and the metabolic modifications induced by influenza virus.

Bronchial epithelial (BEAS-2B) cells were infected or not with influenza A/Scotland/20/74 (H3N2) virus (IAV) at MOI=1 for 4 h and treated or not with succinate (Suc; 4 mg/mL / 24.7 mM) for 20 h.

(a) volcano-plot showing the most significantly regulated canonical pathways determined by microarray analysis compared with mock-treated cells. Each dot represents a specific canonical pathway as

determined by GSEA. Pathway representations result from the magnitude of regulation (z-score, x-axis) and significance ( $-\log_{10}$  adjusted p-value, y-axis). The dashed horizontal line indicates the statistical significance threshold ( $p \leq 0.01$  after adjustment with the Bonferroni correction). The two vertical dashed lines show the z-score threshold (-2: repressed; 2: induced). Colored spots characterize the most highly regulated canonical pathways endowed with statistical significance.

**(b)** Representative inflammatory protein-array blots obtained from the supernatants of control- or IAV-infected- or IAV-infected and succinate-treated cells. The table on the right side indicates the 8 most regulated mediators by succinate.

**(c)** Quantification by ELISA of IL-6, IL-8, IP-10 and RANTES in the supernatants of cells infected or not by IAV and treated or not with succinate.

**(d, e)** Panels show the basal replotted ECAR and OCR **(d)**, and glycolytic capacity (ECAR max) and maximal respiration (OCR max) **(e)** in cells infected with IAV and treated (green symbols) or not (pink symbols) with succinate. Data were normalized with respect to mock-infected, untreated cells (orange symbols), and were also normalized for DNA content.

Data information: Data are the mean  $\pm$  SEM of 6 (panel c) or 4 (panels a, d, e) independent experiments.

Statistical analysis was performed using the Kruskal-Wallis test with Dunn's post-test **(c, d, e)** ( $*P < 0.05$ ) and ANOVA with Holm-Sidak's post-test **(a)** ( $*P < 0.01$ ).

**Figure 3. Succinate does not inhibit the secretion of inflammatory mediators induced by Poly(I:C), but blocks the multiplication of influenza virus in lung epithelial cells.**

Bronchial epithelial (BEAS-2B) cells were challenged with PBS (as control) or with 2  $\mu\text{g/mL}$  Poly(I:C) (PIC) or with influenza A/Scotland/20/74 (H3N2) virus (IAV) at MOI=1 for 4 h and treated or not with succinate (Suc) for 20 h.

**(a)** Levels of IL-6 and IL-8/CXCL8, as measured by ELISA in the supernatants of cells stimulated with (PIC) and subsequently treated or not with succinate.

**(b-e)** A neuraminidase (NA) activity test **(b)**, a Plaque-Forming Units assay **(c)** and scanning electron microscopy **(d)** were used to assess the production of physical **(b, d)** and infectious **(c)** viral particles in

the supernatants of IAV-infected cells, treated or not with succinate. IAV particles budding **are colored in purple**. Scale bar: 1  $\mu$ m.

(e) A neuraminidase activity test was also applied in cells infected or not by IAV and treated or not with malonate (a succinate dehydrogenase inhibitor), in comparison with succinate.

Data information: Data are represented as the mean  $\pm$  SEM of 4 (a) or 6 (b, c, e) independent experiments. Statistical analysis was performed using the Kruskal-Wallis test with Dunn's post-test (\* $P < 0.05$ ).

#### **Figure 4. Succinate protects mice from influenza infection**

8-week-old female C57Bl/6 mice were infected intranasally with 150 pfu of influenza A/Scotland/20/74 (H3N2) virus (IAV) and treated or not simultaneously with 4 mg of succinate (Suc; by the intranasal route).

(a-h) Some mice were euthanized at 4 days post-infection and lungs as well as BAL fluids were collected to determine: (a) the viral load by a plaque forming unit assay; (b) the viral protein expression by Western blotting followed by a relative quantification (c), (d) the levels of 111 additional mediators using a specific protein-array; (e, g) the levels of KC, IL-6 and MPO by ELISA; (f) the number of immune and inflammatory cells by flow cytometry; (h) tissue lesions in lung sections stained with hematoxylin-eosin and further assessed by microscopy. Scale bar: x6/20  $\mu$ m. All data are represented as the mean or the mean  $\pm$  SEM and are cumulative of 2 independent experiments with 5 animals each. (i, j) In separate experiments, body weight loss (n=8) (i) and animal survival (n=10) (j) were monitored daily. Data are represented as the mean  $\pm$  SEM.

Data information: Statistical analysis was performed using the Mann-Whitney test (a, c, h, i), the log rank test (j) and the Kruskal-Wallis with Dunn's post-test (e, f, g), (\* $P < 0.05$ ).

#### **Figure 5. Succinate impairs the intracellular trafficking of influenza virus.**

(a) Schematic representation of the IAV replication cycle. After endocytosis, the viral ribonucleoprotein (vRNP) complexes are transported into the nucleus. Viral RNAs (vRNAs) serve as templates for the synthesis of messenger RNAs (mRNAs) and complementary RNAs (cRNAs) are used for the replication

of vRNAs. mRNAs are exported in the cytoplasm for translation. Some proteins are transported back to the nucleus to form new vRNPs with neosynthesized vRNAs. Newly synthesized vRNPs are exported in the cytoplasm *via* the CRM1 protein. HA, NA, M2 proteins and the vRNPs are transported to the plasma membrane for assembly and budding of the progeny virions.

**(b-f)** Human bronchial epithelial BEAS-2B cells were infected with A/Scotland/20/74 (H3N2) virus (IAV) at MOI=1. After 4 h, cells were treated or not with succinate (Suc; 4 mg/ml) up to 20 h. The effect of succinate on IAV transcription **(b)** and protein expression **(c)** were assessed by RT-qPCR to quantify the M1 viral mRNA and Western blotting to detect viral proteins ( $\beta$ -actin was used as a loading control), respectively. **(d-f)** Human alveolar epithelial A549 cells were infected with the recombinant influenza A/WSN/33 virus expressing a fusion NS1-eGFP protein at MOI= 0.5 for 4 h, then treated with 4 mg/mL of succinate. A549 cells were monitored for 24 h using a BioStation IM-Q device. **(d)** Single-cell dynamics of the nuclear/cytoplasmic fluorescence ratio. **(e)** Single-cell dynamics of cell death as assessed by morphological analysis. **(f)** Quantification of the nuclear/cytoplasmic fluorescence ratio measured at 13h post-succinate treatment. Data are represented as the mean  $\pm$  SEM of 3 biological replicates **(b-c)** or 3 independent experiments **with 3 technical replicates each (d-f)**. Statistical analysis was performed using the Mann-Whitney test **(b-e)** or t-test **(f)**, (\* $P < 0.05$ ).

**Figure 6. The anti-influenza virus effect of succinate involves the nuclear retention of NP and NS1 proteins.**

**(a-c)** Human bronchial epithelial BEAS-2B cells were infected with influenza A/Scotland/20/74 (H3N2) virus (IAV) at MOI=1 for 4 h, then washed and treated or not with succinate (Suc; 4 mg/mL) for 20 h. **(a, c)** Expression of IAV proteins (*i.e.* PA, PB2, M2, M1, NP, NS1) was analyzed by confocal microscopy using specific antibodies. Viral proteins are stained in green, DNA in blue and actin in red. For a given antibody, pictures were taken on the exact same day with the same laser power settings, Pictures are representative of five independent experiments. Scale bar 10  $\mu$ M. **(b)** Relative nuclear intensity of NS1 or NP was determined by using the Intensity Ratio Nuclei Cytoplasm Tool. Seven (NS1) or nine (NP) random images were collected *per* treatment with at least 5 cells *per* field. **Data are**



represented as the mean  $\pm$  SEM. Statistical analysis was performed using the Mann-Whitney test, (\* $P < 0.05$ ).

**Figure 7. Nuclear retention of NP -and not NS1- is a key mechanism underlying the anti-IAV effect of succinate.**

(a-c) Human bronchial epithelial BEAS-2B cells were infected for 4 h with influenza A/PR/8/34 (H1N1) virus, either wild-type (PR8 WT; at MOI=10 (a, b)) or carrying a deletion of the NS1 coding sequence (PR8 $\Delta$ NS1; at MOI=4 (c)), and subsequently treated or not for 20 h with 4 mg/mL of succinate (Suc). Expression of NP (a, c) and NS1 (a) proteins was analyzed by confocal immunofluorescence microscopy. Viral proteins are stained in green, DNA in blue and actin in red. For a given antibody, pictures were taken on the exact same day with the same laser power settings. They are representative of three independent experiments; scale bar 10  $\mu$ M. (b) Neuraminidase (NA) activity in the supernatants of epithelial cells infected by PR8 WT treated or not with succinate. Data are represented as the mean  $\pm$  SEM of 4 independent experiments. Statistical analysis was performed using the Student's t-test, (\* $P < 0.05$ ).

**Figure 8. Succinate reduces the assembly of influenza virus vRNPs by inducing succinylation of NP at K87, a highly conserved amino acid probably involved in vRNA binding.**

Human bronchial epithelial BEAS-2B cells were infected with the influenza A/Scotland/20/74 (H3N2) virus (IAV) at MOI=1 for 4 h, and subsequently treated or not with 4 mg/mL of succinate (Suc) for 20 h.

(a, b) Cells were stained using a monoclonal antibody that specifically recognizes “NP-vRNA” complexes, but not RNA-free NP, and confocal microscopy (a) was performed (green staining). The value raw integrated density (RawIntDen, which is the sum of all pixel values in the ROI (region of interest)) was further measured (b).

(c) Cells were lysed and proteins were digested to peptides with Lys-C and trypsin. Then, succinylated peptides were isolated directly from protease-digested protein extracts by immunoaffinity purification (IAP) using an antibody specific for the succinyl-Lysine motif. Next, the modified peptides were further

analyzed by LC-MS/MS. Box plots show the distribution of intensities of the succinylated NP “YLEEHPSAGK87succDPK” peptide, computed as the integrated mass spectrometry peak area of the modified K87 succinyl peptide (n=3). The boxplots whiskers correspond to the minimum and maximum values, while the central band is the median. The first and third quartiles (boxes) are merely the average values between the median and the extrema.

(d) Interaction of recombinant of wild-type NP (NP K87) or a K87E mutant protein (NP K87E) with the indicated synthetic polyUC RNAs as measured by fluorescence anisotropy.

(e) Human bronchial epithelial BEAS-2B cells were infected with a A/Scotland/20/74 (H3N2) virus (IAV) carrying a wild-type NP (NP WT) or with the corresponding mutated virus bearing a NP with a K87R substitution (NP K87R). Cells were infected by either virus at MOI=1 for 4 h, then washed and treated or not with 4 mg/mL of succinate for 20 h. Localization of NP proteins was analyzed by confocal immunofluorescence microscopy. Scale bar: 10  $\mu$ M. Pictures are representative of three independent experiments.

(f) Relative nuclear intensity of NP was determined by using the Intensity Ratio Nuclei Cytoplasm Tool.

(g) Plaque-Forming Unit assays determined the production of infectious viral particles in cell supernatants.

Data information: Data are represented as the mean  $\pm$  SEM of 3 biological replicates with (g) or without (a, c-e) 2 technical replicates each. 8 (b) or at least 10 (f) random images were analysed *per* treatment with a minimum of 5 cells *per* field. Statistical analysis was performed using the Mann-Whitney test (b, c, d, f) or paired t-test (g), (\* $P < 0.05$ ).

### **Figure 9. Hypothetical model of the anti-influenza activity of succinate**

Succinate triggers a unique succinylation modification of K87 in the NP of IAV which further alters the electrostatic environment of the vRNA binding site. As a result, the formation of vRNPs particles is impaired. This further contributes to an inhibition of viral multiplication as well as viral-induced inflammatory response. *In vivo*, IAV-infected mice treated intranasally with succinate are more resistant to the development of acute pneumonia.

## EXPANDED FIGURES LEGENDS

### **Figure EV1. Anti-influenza effect of succinate is more potent in multicycle replication condition than in single cycle replication condition.**

BEAS-2B were infected with influenza A/Scotland/20/74 (H3N2) virus (IAV) at MOI=1 (single cycle replication) or at MOI=10<sup>-3</sup> (multicycle replication) for 4h and treated or not with succinate (Suc) for 20h. 2 µg/mL of TPCK treated Trypsin were added simultaneously to succinate to promote multicycle replication.

(a, b) Plaque-Forming Unit assays determined the production of infectious viral particles in cell supernatants.

(c) The effect of succinate on IAV transcription was assessed by RT-qPCR to quantify M1 viral mRNA.

Data information: Data are represented as the mean ± SEM of 3 independent experiments. Statistical analysis was performed using paired t-test (a, b) or one sample t-test (c), (\**P* < 0.05).

### **Figure EV2. Nucleoprotein localisation determined by flow cytometry.**

BEAS-2B cells were infected with influenza A/Scotland/20/74 (H3N2) virus (IAV)) at MOI 1 for 4h and treated or not with succinate (Suc) for 20h. Nucleoprotein (NP) expression was assessed by flow cytometry using two different permeabilization buffers, one allowing whole cell fluorescent staining of NP, the other only the NP-associated to the cytoplasmic compartment (by subtraction, nuclear-associated NP signal was extrapolated). Data are represented as the mean ± SEM of 4 independent experiments. Statistical analysis was performed using ANOVA with Sidak's post test, (\**P* < 0.05).

### **Figure EV3. Succinate does not alter the CRM1-dependent transport pathway or the NP oligomerization.**

(a, b) Human bronchial epithelial BEAS-2B cells were infected or not with the A/Scotland/20/74 (H3N2) virus (IAV) at MOI=1 for 4 h, and subsequently treated or not with 4 mg/mL of succinate for 20 h (a) or with 10 mM of the CRM1 inhibitor leptomycin B (LMB; *middle panels* in b). The expression of CRM1 was analyzed by Western blotting (a). Expression of the viral protein NEP/NS2 was analyzed

1107 by confocal fluorescence microscopy **(b)**. NEP/NS2 is stained in green, nuclear DNA in blue and actin  
1108 cytoskeleton in red. Scale bar: 10  $\mu$ M.

1109 **(c)** The formation of NP oligomers and monomers was assessed by Western blotting under non-reducing  
1110 and reducing conditions.

1111 Data information: Pictures are representative of three independent experiments.

1112

1113 **Expanded Movies EV1. Intracellular trafficking of influenza virus, in absence of succinate**  
1114 **treatment.** A549 cells grown on cell culture in micro-wells were infected with NS1-eGFP-WSN at  
1115 an MOI of 0.5 pfu/cell. Pictures were taken every 10 min starting at 1 h post-infection and continuing  
1116 until 24 h post-infection.

1117

1118 **Expanded Movies EV2. Succinate impairs the intracellular trafficking of influenza virus.**  
1119 A549 cells grown on cell culture in micro-wells were infected with NS1-eGFP-WSN at an MOI of  
1120 0.5 pfu/cell and treated with 4mg/ml of succinate. Pictures were taken every 10 min starting at 1 h  
1121 post-infection and continuing until 24 h post-infection.

1122

1123

1124

1125

## APPENDIX FIGURES LEGENDS

### **Appendix Figure S1. Effect of succinate on gene expression in influenza virus-infected human bronchial epithelial cells.**

Human bronchial epithelial BEAS-2B cells (4 replicates *per* condition) were infected or not (“Ctrl”) with the A/Scotland/20/74 (H3N2) virus (IAV) at MOI=1 and were treated or not with succinate (4mg/mL). After 24 h of infection, cells were lysed and total RNA was purified and processed to hybridize pangenomic microarrays. Differentially expressed genes (p-value  $\leq 2$ ) between two conditions (“IAV-infected cells” vs. “control cells” and “IAV-infected cells treated with succinate” vs. “control cells”) were then selected to perform a gene ontology analysis. Significantly enriched pathways were identified using Ingenuity Pathway Analysis (IPA) and are represented as a bar plot representing the right-tailed Fisher’s exact test that was used to calculate a p-value (probability that each canonical pathway assigned to that data set is due to chance alone).

### **Appendix Figure S2. Succinate is not cytotoxic.**

Human bronchial epithelial BEAS-2B cells were treated or not with increasing doses (**a**) or 4 mg/mL (**b**) of succinate for 24 h. Cell proliferation and cytotoxicity were further assessed by an MTS test (**a**) and by flow cytometry using a Live/Dead staining/Annexin V/Propidium Iodide co-staining (**b**), respectively. Data are represented as the mean  $\pm$ SEM. Statistical analysis was performed using the Kruskal-Wallis test (**a**, n=3) and the multiple t-test (**b**, n=6).

### **Appendix Figure S3. Scanning and transmission electron microscopy of IAV-infected lung epithelial cells, treated or not by succinate.**

Bronchial epithelial (BEAS-2B) cells were infected with influenza A/Scotland/20/74 (H3N2) virus (IAV) at MOI=5 for 4 h and treated or not with succinate (Suc) for 20 h. Scanning (**a**) and transmission (**b**) electron microscopy were used to assess the production of physical viral particles in the supernatants of IAV-infected cells, treated or not with succinate. Scale bar: 1  $\mu$ M.

**Appendix Figure S4. Antiviral effect of succinate in distinct airway epithelial cell lines.**

Human lung epithelial (a) BEAS-2B, (b) 16HBE14o- or (c) A549 cells were infected with influenza A/Scotland/20/74 (H3N2) virus (IAV) at MOI=1 for 4h and treated or not with succinate (Suc) for 20h. Plaque-Forming Units assay determined the production of infectious viral particles in cell supernatants. Data are represented as the mean  $\pm$  SEM of 3 independent experiments. Statistical analysis was performed using paired t-test.

**Appendix Figure S5. Datasheet of mouse XL cytokine array kit.**

*Upper panels:* High resolution scans of original mouse XL cytokine arrays, *Middle panel:* overlay template and coordinates; *Lower panels:* reading appendix.

**Appendix Figure S6. Flow cytometry gating strategy.**

Surface gating used to define immune cell subsets in Figure 4.

**Appendix Figure S7. Mass spectrometry methodology and profiles.**

(a) Human bronchial epithelial BEAS-2B cells were infected with A/Scotland/20/74 (H3N2) virus (IAV) at MOI=1 for 4 h, and subsequently treated or not with 4 mg/mL of succinate for 20 h. Cells were lysed and proteins were digested to peptides with Lys-C and trypsin. Succinylated peptides were isolated directly from protease-digested cellular protein extracts by immunoaffinity purification (IAP) using an antibody specific for the succinyl-Lysine motif, and the modified peptides were further analyzed by LC-MS/MS. (b) Representative MS/MS spectra of succinylated and non-succinylated NP peptides.

**Appendix Figure S8. Similar growth of wild-type K87 and mutant K87R IAV strains.**


Human bronchial epithelial BEAS-2B cells were infected with influenza A/Scotland/20/74 (H3N2) (IAV) strains carrying a wild-type NP (“WT”) or a NP with a K87R substitution (“K87R”). Cells were infected by either virus at MOI=1 for 4 h, then washed and left untreated for 20 h. Plaque-Forming Units assay determined the production of infectious viral particles in cell supernatants. Data are represented

as the mean  $\pm$  SEM of 4 independent experiments. Statistical analysis was performed using the Mann-Whitney test.

**Appendix Figure S9. Impact of the NP structure on its interaction capacity with viral RNA.**

*Panel 1:* In NP, the Lysine (K)87 is a positively charged amino acid which is key in the interaction with negatively charged vRNA. *Panel 2:* Conversely, glutamic acid (E) is a negatively charged residue. As a result, NP K87E mutant interacts less with vRNAs. *Panel 3:* In succinate-treated cells, the addition of a succinyl group to the NP K87 residue neutralizes the positive charge of lysine and imparts a negative charge, thus altering the NP-vRNA interaction as well.

**Appendix Table S1. List of all reagents and resources used**




d



Patients' characteristics	No-IAV infection (n=7)	IAV infection (n=9)	<i>P</i> *
Indication for mechanical ventilation	Coma	Respiratory failure	
Age (y.o.), median [IQR]	57[36-65.5]	57 [44 – 62.5]	0.698
Sexe, men/women	4/3	7/2	0.60
SAPS II, median [IQR]	44.5 [36-62.8]	42[29-45]	0.323
Charlson Comorbidity Index, median [IQR]	1.5[0.75-3]	2[1-3]	0.68
Chronic respiratory disease			
COPD	0/7	0/9	na
Asthma	0/7	0/9	na
Current smoker	1/7	2/9	1.0
Body Mass Index (kg/m <sup>2</sup> ), median [IQR]	32.5[24.5-36.4]	26.9[24.2-27.5]	0.25
Time flu symptoms-to-sample, median [IQR]	na	9[7-18]	na
Time ventilator support-to-sample, median [IQR]	4.0[1.5-7.0]	5.0[4.0-7.0]	0.99
Leucocyte counts			
in blood (G/L), median [IQR]	10.6[7.1-13]	15.4[6.9-17.5]	0.28
in tracheal aspirate (n/FOV**)	40[25-55]	30[20-150]	0.36
Microbial examination of tracheal aspirate			
Positive bacterial culture	5/7	2/9	0.13
Positive PCR for Influenza	na	9/9	na

\*Fisher's exact test for contingency or two-tailed Test for median comparison. \*\* Count by microscope field of view (mean of 5 counts)







**a**

**b**


**C**




**d**




e





# Guillon et al. Figure 3



Guillon *et al.* Figure 4



a




b. qRT-PCR


c. Western Blotting

d,e,f. Live imaging


b




c




d




e




f









**a**




**b**





**c**







a




b





c




d




d. Fluorescence anisotropy


e. Confocal microscopy  
f. Relative protein quantification  
g. Viral titration


e




f



g











# Guillon *et al.* Figure EV 1


**a**




**b**




**c**




# Guillon *et al.* Figure EV2




# Guillon *et al.* Figure EV3



**a**



**b**



**c**

